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Tumor Suppressive Effects of the Beta-2 Adrenergic 
Receptor and the Small GTPase RhoB 
Adam Carie 
ABSTRACT 
 
Receptor tyrosine kinases such as ErbB2 contribute greatly to human 
malignant transformation, but the role that other receptors such as the β2 
adrenergic receptor play in cancer is ill defined.  Furthermore, while some 
GTPases such as Ras and RhoA promote oncogenesis, RhoB has been 
suggested to have tumor suppressive activity.  In this thesis the tumor 
suppressive activity of β2 adrenergic receptors (β2 AR) through blockade of the 
Ras/Raf/Mek/Erk pathway is demonstrated.  Furthermore, this thesis provides 
strong evidence in support of a tumor suppressive activity of RhoB, but not 
RhoA, in delaying EbB2 mammary oncogenesis in a transgenic mouse model. 
Chapter 1 describes a chemical biology approach that identifies a beta 2 
adrenergic receptor agonist, ARA-211 (also known as pirbuterol) that suppresses 
the growth of cultured cells and of human tumors grown in nude mice by a 
mechanism involving stimulation of the β2 AR, cAMP production and activation of 
PKA, which in turn leads to the inactivation of C-Raf, Mek1/2 and Erk1/2.  
Chapter 2 describes the translation of these findings by ex-vivo treatment of fresh 
 xi
human tumor biopsies, with the ultimate goal of validating this novel therapeutic 
approach.  Chapter 3 describes the generation of transgenic mice that over 
express ErbB2 along with either RhoB or RhoA to determine the effects of these 
two small GTPases on ErbB2-mediated mammary tumorigenesis.  The findings 
indicate that overexpression of RhoB, but not RhoA, results in decreased 
multiplicity and delay in the tumor onset mediated by ErbB2 overexpression. 
In summary, this thesis work resulted in the discovery of how crosstalk 
between the β2 AR/cAMP/PKA circuit with the Raf/Mek/Erk1/2 cascade leads to 
tumor suppression; and the discovery of the suppression of ErbB2-mediated 
breast cancer by the GTPase RhoB.   
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Background and Significance 
 
Accumulation of genetic alterations by overexpression or hyperactivation 
of oncogenes and inactivation or deletion of tumor suppressor genes leads to 
aberrant signal transduction, which confers the transforming cellular properties 
that result in hallmarks of cancer.  These properties include self-sufficiency in 
growth signals and resistance to anti-growth signals, evasion of apoptosis, the 
ability to induce and sustain angiogenesis, the capacity to metastasize and 
invade foreign tissue, and the potential to replicate limitlessly.  Ultimately, the 
aberrant signal transduction provides a mechanism for the transformation of 
normal cells to malignant.  In general, this aberrant signaling will be the focus of 
my thesis, however, there are a multitude of irregular signaling pathways found in 
cancer cells.  Figure 1 demonstrates just a few of the many pathways known to 
be misregulated in cancer.   
 
  
Figure 1.  Cancer cells contain numerous, aberrant signal transduction 
circuits
β2AR
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One of the major signal transduction pathways that become aberrant in 
cancer is that of receptor tyrosine kinases (RTKs).  For example, receptor 
overexpression or mutation of kinase domains leads to persistent activation of 
downstream signals.  The ErbB family of receptor tyrosine kinases is the most 
intensely studied.  There are four members of the ErbB family: ErbB1 (EGFR, 
Epidermal Growth Factor Receptor), ErbB2, ErbB3 and ErbB4(1).  Ligands for 
these receptors induce homo or heterodimerization leading to activation of 
intracellular tyrosine kinase domains(2, 3).  There is no known ligand for ErbB2, 
but epidermal growth factor (EGF) can induce heterodimerization of ErbB1 and 
ErbB2(4, 5).  Similarly, neuregulins are known to activate ErbB3 and ErbB4, 
which can both complex with ErbB2(6).  When activated, ErbB2 heterodimers are 
potent signal transducers, in part, due to their relatively slow rates of receptor 
internalization and ligand dissociation(4, 7).  ErbB2 gene amplification leading to 
receptor overexpression is common among breast cancer, occurring in 
approximately 26% of all cases(8).  Signal transduction pathways downstream of 
ErbB2, and many other growth factor receptors, become aberrant in cancer, 
including persistent activation or mutation of Ras proteins(3).  Ras is a central 
signaling node found mutated in 30 % of all human tumors(9) that confers 
transforming signals through activation of downstream cascades such as 
Raf/Mek/Erk, PI3K/Akt and RalGDS/RalA and RalB, as shown in Figure 2.  
These signals have been shown to result in cell proliferation, survival and 
metastasis when hyperactive(10).  
  
Raf
Mek
Erk
Akt
Grb2 P
Ras
SOS
PI3K
Ras
P
RalGDS
RalA/B
Erk
DNA
Nucleus
Fos
Myc
RTK
PDGFVEGF
EGF
Figure 2.  Aberrant signaling through receptor tyrosine kinases (RTKs) 
and downstream signaling through Ras is well characterized
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In addition to Raf, PI3K and RalGDS mediating Ras cancer-causing 
activity, other small G-proteins such as RhoA also mediate Ras oncogenesis.  
The mechanism by which Ras communicates with RhoA is unknown, but there is 
evidence supporting indirect activation of RhoA by Ras resulting in proliferation 
and increased cell motility(11, 12).  There is evidence supporting regulation of 
RhoA and Rac1 activity by the Mek/Erk MAPK pathway(13).  Rho kinase (RhoK) 
is an immediate downstream effector of RhoA that stimulates proliferation and 
migration, possibly through c-MYC as a downstream effector(14).  Surprisingly, a 
close family member of RhoA, RhoB which shares 86% amino acid identity with 
RhoA, has been suggested to have tumor suppressive activity.  Our lab and 
others have demonstrated in-vitro that overexpression of RhoB, but not RhoA, 
antagonizes the transforming activity of ErbB2, EGFR, H-Ras, PI3K and Akt, but 
not c-Myc(15, 16).  These studies also provide evidence supporting the anti-
tumor effects of RhoB through inhibition of phospho-Akt as illustrated in Figure 3.   
Figure 3. RhoB, a close family member of RhoA, antagonizes  Ras 
malignant transformation and has been suggested to have tumor 
suppressive activity
Akt
PI3K
Grb2 P
Ras
SOS
DNA
Nucleus
PDGFVEGF
EGF
RhoB
RhoB
Malignancy, Apoptosis,
Uncontrolled growth, 
Migration, Invasion,
Metastasis
RTK
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Furthermore, other groups have demonstrated that RhoB is mainly localized to 
endosomes and can limit cell proliferation, survival and invasion and 
metastasis(17, 18).  RhoB has been suggested to target K-Ras, B-Raf, Cdc6, 
spindle checkpoint assemblies, and Lipocortin to induce apoptiosis regulated by 
inhibition of farnesyl transferase for cancer therapy(19).  RhoB knockout mice 
studies show that RhoB is not essential to normal development, however the 
mice showed an increased sensitivity to chemical carcinogenesis by 7,12-
dimethylbenz[α]anthracene as well as increased efficiency of intraperitonel tumor 
formation(20).  Likewise, mouse embryonic fibroblasts lacking RhoB showed 
increased sensitivity to Ras and E1A transformation-mediated cell adhesion, and 
increased sensitivity to TGFβ signaling(20).  Also, targeted ablation of RhoB in 
transformed cells was shown to protect cells from Taxol-induced apoptosis, but 
not doxorubicin or UV irradiation, suggesting an apoptotic checkpoint role of 
RhoB in actin cytoskeleton remodeling(21).  Similarly, IHC studies in paraffin-
embedded tumor specimens from lung and head and neck cancer patients have 
demonstrated that RhoB expression is decreased as cancers progress from 
hyperplastic to deeply invasive carcinoma by immunohistochemistry(22, 23).  
Finally, oncogenic proteins such as ErbB2, EGFR, Ras, PI3K and Akt all repress 
the expression of RhoB at the transcriptional level(15).  Taken together, these 
studies suggest that as normal cells acquire initial genetic alterations, RhoB is 
induced and serves as a gatekeeper to suppress the growth and induce 
apoptosis of these cells.  However, as the cells accumulate more genetic 
alterations such as ErbB2, EGFR, Ras, PI3K and Akt, these transcriptionally 
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repress RhoB.  Support for this hypothesis was provided by the Sebti lab that 
showed that forced expression of RhoB reverses malignant transformation by 
these oncogenes(15).  However, in-vivo evidence in animal models to support 
the above hypothesis is lacking.  Chapter 3 of this Thesis provides evidence for 
the role of RhoB, but not its closely related family member RhoA, in suppressing 
human ErbB2-driven breast cancer in a mouse model where ErbB2 expression is 
regulated by the mouse mammary tumor virus (MMTV) promoter.  This model is 
highly relevant to human breast cancer where ErbB2 is believed to contribute to 
at least 26% of the progression of this disease(24).  In Chapter 3 the RhoB and 
RhoA transgenic mice were crossed with the ErbB2 overexpressing mice to 
study the effects of RhoB and RhoA overexpression on ErbB2-mediated tumor 
onset, multiplicity and growth rate.   
 In Chapter 1 and 2 of this thesis the relevance of the crosstalk 
between the Ras/C-Raf/Mek1/2/Erk1/2 and the beta 2 adrenergic receptor (β2 
AR) signaling circuits to suppression of tumor growth is studied.  The β2 AR is a 
well-studied and characterized pathway in normal cell physiology.  However, we 
became interested in this signal transduction pathway as we initially searched for 
novel inhibitors of the Raf/Mek/Erk kinase cascade.  Adrenergic receptors belong 
to a large super-family of membrane spanning proteins known as G-protein 
coupled receptors.  This family contains over 500 members, each containing a 
membrane-spanning domain of seven α-helices principally made up of 22-28 
hydrophobic amino acids each(25-27).  When a ligand binds its specific receptor 
a conformational change takes place that allows for the activation of specific 
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heterotrimeric G-proteins.  Upon activation, the G-proteins active subunit, such 
as Gαs, releases GDP and binds GTP, allowing the active subunit to dissociate 
from the other subunits (such as β & γ) and affect other proteins in its signal 
transduction pathway.  In some cases the βγ-dimer can also transmit signals that 
mediate receptor response.  It is well documented that adrenergic receptors 
regulate many facets of the sympathetic nervous system.  One of the first second 
messenger systems discovered was the adrenergic receptor-cAMP-Ca++-
pathway.  Stimulants such as epinephrine and isoproterenol bind the β-
adrenergic receptors resulting in the release of Gαs subunits, which stimulate the 
enzyme adenyl cyclase(28, 29).  Adenyl cyclase then catalyses the conversion of 
ATP to cAMP, leading to the activation of cAMP-dependant protein kinases, 
ultimately resulting in the opening of Ca++ channels and a biological response 
such as increased heart rate(30, 31).  On the other hand, inhibitory agonists such 
as adenosine cause the release of inhibitory Gαi subunits that decrease adenyl 
cyclase activity.  The extensive research in this area of adrenergic receptor 
function has lead to the discovery of many small molecule drugs that target the 
different receptors, and lead to physiological responses in heart rate, smooth 
muscle contraction or dilation and nerve conduction.  More recent research has 
demonstrated that cAMP signaling can modulate normal cell proliferation through 
crosstalk with signal transduction pathways such as the Raf/Mek/Erk1/2 kinase 
cascade. 
Cell proliferation in complex organisms is controlled by numerous systems 
involving hundreds of different proteins and signaling mechanisms.  One way in 
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which cAMP is involved in cell proliferation is through the modulation of the 
mitogen activated protein kinase (MAPK) cascade.  The effects of cAMP on the 
levels of Erk1/2 activation in normal cells are widely variable depending on the 
type of cells and the intracellular pathways that crosstalk in these cells.  One 
mechanism in which ERKs are activated via cAMP has been shown to involve 
stimulation of B-Raf, which activates the Mek/Erk1/2 pathway(32, 33).  The 
means through which cAMP activates B-Raf is still unclear, yet probable 
mechanisms have been proposed involving PKA, Src, and Rap-1(32-35).  In cells 
that express B-Raf it is suggested that Rap-1 activation by Src leads to 
stimulation of B-Raf and ultimately in the activation of Erk1/2(34).  Furthermore, 
In some leukemia and normal kidney cells studies have shown that cAMP-GEFs, 
or EPACs (exchange proteins directly activated by cAMP), have an affinity for 
Rap-1(36-38).  This demonstrates yet another mechanism in which cAMP can 
stimulate Erk1/2 activity, but in a PKA-independent manner.  While in many 
normal cells, such as rat thyroid cells, bone cells, polycystic kidney epithelium, 
Sertoli cells, cardiac myocytes, granulosa cells, pre-adiposites, pituitary cells and 
PC12 cells, cAMP has been shown to stimulate Erk1/2 and proliferation(39-46), 
only one study in leukemia cells has shown that EPACs activate Erk1/2(47).   
There have also been a multitude of mechanisms proposed for the 
inhibitory consequences of cAMP on the proliferation of normal cells, such as in 
adipocytes, endothelial cells, NIH 3T3 cells, rat fibroblasts, smooth muscle cells, 
hepatocytes and pancreatic acinar cells(40, 48-56).. The mechanisms by which 
this could occur include inhibition of Erk1/2 through a PKA-dependent activation 
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of Rap-1, up-regulation of Erk phosphatases (MKPs), and inhibition of Raf-1 
kinase activity via direct phosphorylation by PKA(49, 57-61).  A generally 
accepted mechanism in which cAMP inhibition of Erk1/2 takes place is through 
the ability of PKA to block Raf-1 activity.  Upon cAMP stimulation the catalytic 
subunits of PKA are free to phosphorylate downstream targets, including Raf-1.  
Phosphorylation of Raf-1 by PKA on serine 621 inhibits the Raf-1 kinase 
domain(50, 52, 62-65).  Other inhibitory phosphorylation sites on Raf-1 have 
been proposed, including serine 259 and 43, but it is not known if PKA subunits 
phosphorylate these sites in-vivo.  An alternative mechanism that has been 
proposed is that of PKA activating c-Src, in turn activating Rap-1, which in the 
absence of B-Raf, competes with C-Raf for binding sites to Ras(34, 37, 38, 59).  
While in normal cells extensive studies have investigated the role of cAMP in cell 
proliferation, only a few studies were carried out in tumor cells.  These studies 
showed that in breast cancer and neuroblastoma cancer cells, cAMP induction 
results in inhibition of DNA synthesis and induction of apoptosis, respectively(66, 
67).  However, the effects of cAMP on inhibition of the Ras/Raf/Mek/Erk pathway 
has not been investigated in tumors.  We believe that there is an unmet need to 
investigate whether stimulation of the adrenergic receptor can be used as a novel 
approach to cancer chemotherapy.  Fundamental questions that need to be 
addressed include first to determine whether there is crosstalk between the β AR 
signaling circuit and the Ras/Raf/Mek/Erk circuit.  Second, if this crosstalk exists, 
then to determine whether β AR stimulation results in activation or inactivation of 
the MAPK pathway, and whether this affects several hallmarks of cancer cells 
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such as uncontrolled proliferation, anchorage-dependent and –independent 
growth, apoptosis and tumor growth in animals.  Third, the mechanism of the 
crosstalk should be investigated as well.  Therefore, determining how, for 
example, stimulation of the β AR regulates the Raf/Mek/Erk circuits in cancer is 
of prime importance.  Other important questions that need to be addressed are 
determining the types of β AR involved (i.e. β1 or β2).  Finally, the prevalence of 
the β AR circuits in fresh tumor biopsies, especially those that contain 
persistently activated Ras/Raf/Mek/Erk signaling needs to be investigated.  
Chapters 1 and 2 of this Thesis will address the important issues above.   
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Chapter 1 
 
A Chemical Biology Approach Identifies a Beta-2 Adrenergic Receptor 
Agonist that Causes Human Tumor Suppression by Blocking the C-
Raf/Mek1/2/Erk1/2 Pathway 
 
Data from this Chapter was published by Adam Carie and Said Sebti in the 
journal Oncogene, issue 26, 3777-3788, 2007. 
 
All of the work in this Chapter was performed by Adam Carie except for Figure1 
cytoblot, which was performed by Adrian Kenny 
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Abstract 
 
A chemical biology approach identifies a beta 2 adrenergic receptor 
(β2AR) agonist ARA-211 (pirbuterol), which causes apoptosis and human tumor 
regression in animal models.  β2AR stimulation of cAMP formation and PKA 
activation leads to C-Raf (but not B-Raf) kinase inactivation, inhibition of Mek1/2 
kinase and decreased phospho-Erk1/2 levels.  ARA-211-induced inhibition of the 
C-Raf/Mek1/2/Erk1/2 pathway is mediated by PKA and not EPAC.  ARA-211 is 
selective and suppresses P-Erk1/2 but not P-JNK, P-p38, P-Akt or P-STAT3 
levels.  β2AR stimulation results in inhibition of anchorage-dependent and -
independent growth, induction of apoptosis in vitro and tumor regression in vivo.  
β2AR antagonists and constitutively active Mek-1 rescue from the effects of 
ARA-211 demonstrating that β2AR stimulation and Mek1/2 kinase inhibition are 
required for ARA-211 antitumor activity.  Furthermore, suppression of growth 
occurs only in human tumors where ARA-211 induces cAMP formation and 
decreases P-Erk1/2 levels.  Thus, β2AR stimulation results in significant 
suppression of malignant transformation in cancers where it blocks the C-
Raf/Mek1/2/Erk1/2 pathway by a cAMP-dependent activation of PKA, but not 
EPAC.   
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Introduction 
 
Malignant transformation of normal cells to cancer cells requires the 
acquisition of several oncogenic traits such as uncontrolled cell division, 
resistance to programmed cell death (apoptosis), invasion and angiogenesis(68).  
These malignant transformation traits are believed to be the consequence of the 
accumulation of genetic alterations that result in deregulated signal transduction 
circuits(68).  Such genetic alterations can simply be point mutations that result in 
constitutive activation of key signal transducers such as Ras, a GTP/GDP 
(gunosine triphosphate/guanosine diphosphate) binding GTPase that contributes 
to 30% of all human cancers(9).  Alternatively, these alterations can involve 
entire genes such as the receptor tyrosine kinases epidermal growth factor 
receptor and ErbB2 that are found over expressed in many major human cancers 
such as breast tumors(69, 70).  Often such genetic alterations result in 
constitutive activation of common downstream signal transduction pathways such 
as the mitogen activated protein kinase (MAPK) cascades of several 
serine/threonine kinases including C-Raf, Mek1/2, Erk1/2, p38 and JNK (Jun 
kinase)(64, 71-73).  Other pathways involved in uncontrolled proliferation, 
apoptosis, invasion and angiogenesis also include those mediated by the signal 
transducer and activator of transcription 3 (STAT3) and the serine/threonine 
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kinase Akt(74, 75).  Not only have these oncogenic and tumor survival pathways 
been found constitutively activated in the great majority of human cancers, but 
also their hyperactivation has been associated with poor prognosis and 
resistance to chemotherapy in cancer patients(69, 70).  This has prompted drug 
discovery efforts targeting receptor tyrosine kinases, Ras, C-Raf, Mek, Akt and 
STAT3 to thwart aberrant signal transduction pathways in tumor cells (65, 76-79).  
For example, inhibitors of receptor tyrosine kinases (RTKs), Ras, C-Raf and 
Mek1/2 have all been identified and are at various stages of development(63, 
80).  Some, like the epidermal growth factor receptor (EGFR) kinase inhibitor 
Tarceva, was approved by the FDA for the treatment of patients with lung 
cancer(81).     
Genetic abnormalities that often predispose or lead to cancer, such as 
overexpression of growth factors, mutations leading to constitutive activation of 
cellular receptors, deletion or misregulation of tumor suppressors, or uncontrolled 
signal transduction pathways often signal directly through the small GTPases 
Ras.  Ras proteins are central nodes in the cellular signaling response from 
growth factors and receptors.  They are localized to the cellular membrane 
regions by a lipid post-translational modification known as prenylation(9, 82-87).  
Ras activation occurs through the exchange of guanosine diphosphate 
nucleotides for guanosine triphosphate nucleotides catalyzed by exchange 
factors known as GEFs (guanosine nucleotide exchange factors).  Activated Ras 
proteins can interact with more than 20 downstream effectors, the best-
characterized being Raf, PI3K (phosphatidylinositol-3’-kinase), and Ral 
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GTPases.  These effectors are responsible for the proliferative, prosurvival, and 
differentiation effects from Ras signaling(9, 82-87). 
RasGTP-mediated prosurvival signaling occurs at least in part through 
activation of the regulatory subunit of PI3K, which targets it to the membrane to 
phosphorylate PIP2 (phosphatidylinositol-4,5-bisphosphate), converting it to PIP3 
(phosphatidylinositol-3,4,5-triphosphate)(74, 88, 89).  PIP3 recruits PDK and Akt 
through their PH domains, which leads to the phosphorylation of Akt by PDK1 
and other kinases(74).  Akt is a kinase that has been shown to phosphorylate 
and inactivate pro-apoptotic proteins including BAD and FKHR (forkhead 
homologue 1) transcription factors, leading to survival under circumstances that 
cells would normally undergo apoptosis(74).  Furthermore, PI3K has been shown 
to activate Rac, a Rho family protein that is important for cytoskeletal 
rearrangement leading to transformation, invasiveness and metastasis(90-93).  
The PI3K/Akt pathway has been the focus of major drug discovery and 
development efforts for cancer therapy.   
Another important cellular signaling component downstream of Ras is the 
Ral GDS/Ral pathway.  Ral GEFs, such as RalGDS (Ral guanine nucleotide-
dissociation stimulator), activate the Ras-like Ral GTPase proteins RalA and 
RalB.  Similar to Ras, the Ral proteins are reliant on prenylation, whereby a 20-
carbon lipid geranylgeranyl group is added to the C-terminus, leading to 
membrane anchorage for downstream signaling to effectors(94-98).  The 
downstream effectors of RalA and RalB have been suggested to be involved in 
early transforming events due to aberrant Ras signaling.  Recently, in cell culture 
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models, the RalGEF-Ral pathway was shown to be required for Ras mediated 
transformation(94, 95).  Likewise, in a knockout mouse model lacking RalGDS, 
skin tumors from carcinogen-induced Ras showed impaired growth(99).  
Although RalA and RalB share 85% sequence identity, it has recently been 
discovered that these proteins play distinct roles in anchorage-independent 
growth and cell survival, respectively(94).  Furthermore, our lab has 
demonstrated that Ral proteins are exclusively geranygeranylated, and that 
inhibition of the geranylgeranylation of RalB mediates GGTI-induction of 
apoptosis and inhibition of anchorage-independent growth.  In contrast, inhibition 
of RalA geranylgeranylation mediates GGTI-induced inhibition of anchorage 
independent growth(94).  Currently, GGTI compounds are still in preclinical 
development; however, clinical candidates are not far off from human trials.  
Development of GTPase inhibitors is in its infancy compared to the efforts to 
develop selective kinase inhibitors.  One of the first discovered and most targeted 
kinase pathways is downstream of Ras, and belongs to the mitogen activated 
protein kinase (MAPK) family.    
MAPKs are the effectors in a line of kinases that transduce signals from 
growth factors and mitogens from the cell surface to the nucleus.  With a large 
number of activators the specific physiological message of the external ligand is 
translated into cellular responses.  Depending on the stimuli, these responses 
include proliferation, differentiation, and survival.  There are four major families of 
mammalian MAP kinase proteins.  They are all known to be activated by growth 
factors, but only the Raf/Mek/Erk pathway has not been linked to stress 
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activation.  The p38, JNK and Erk5 pathway are activated by cellular stress, as 
well as by cytokines and growth factors(100).  The signaling circuitry provides 
three steps at which signaling can be positively or negatively regulated.  Once 
activated by upstream signals, the first MAP kinase kinase kinase (MAPKKK) 
phosphorylates MAP kinase kinase (MAPKK), which in turn, phosphorylates 
MAPK kinase (MAPK) to target transcription factors to either activate or repress 
gene expression(100).  These kinases are evolutionarily conserved among 
mammals and are important for development as well as homeostasis. 
The Ras/Raf/Mek/Erk kinase cascade has been scrutinized and targeted 
in the past 20 years.  Ras activation of Raf proteins, most notably C-Raf and B-
Raf, leads to activation of Mek kinases(87, 101, 102).  The pathway bottlenecks 
at Mek, as Mek1 and Mek2 are the only known activators of Erk1 and Erk2.  
These terminal serine threonine kinases phosphorylate and regulate over 150 
different proteins(103).  Most of the activated Erk1/2 goes to the nucleus where it 
activates transcription factors that control gene expression and functions such as 
cell proliferation and evasion of apoptosis(104).  These effectors play an 
important role in the oncogenic signaling of Ras.  
The Raf serine/threonine kinases (A-Raf, B-Raf and C-Raf or Raf-1) are 
best known for their activation of downstream Mek kinases.  The isoforms are 
similar in their effectors, but have different expression profiles.  C-Raf is 
ubiquitously expressed, where A-Raf is generally found in the urogenital organs, 
and B-Raf is primarily neuronal(65).  Retroviral Raf protein is a potent oncogene 
whose constitutive activation results in cellular transformation.  The B-Raf 
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isoform is found mutated in many human tumors, including melanoma, colon, 
lung and thyroid tumors((105-107).  The majority of mutations of B-Raf found in 
cancer are of the V600E variety(106).  The most recent molecularly targeted 
therapies against mutated B-Raf have poor preclinical profiles or off target 
effects(108).  However, a newly developed inhibitor, PLX4720, demonstrates 
selective inhibition of mutated B-Raf kinase activity and promising antitumor 
efficacy for melanoma(109).  C-Raf and B-Raf both mediate signals downstream 
of Ras.  Ras activation brings Raf to the membrane where it interacts with many 
signaling partners.  This interaction results in the phosphorylation of Raf.  The 
activation or inhibition of C-Raf kinase activity is dependent on the tyrosine, 
serine or threonine amino acid site where the phosphorylation events occur(110, 
111).  Known activators of C-Raf include Src and PKC, which phosphorylate C-
Raf on S388, T491, S494 and S499(112).  Deactivators include Akt and PKA, 
which phosphorylate C-Raf on S43, S621 and S259(112).  Although many 
pathways feed into Raf signaling, currently the only validated physiologically 
relevant downstream targets of C-Raf are the Mek1/2 MAP kinase proteins(111).  
C-Raf has been widely targeted for cancer therapy.  Both small molecule 
inhibitors as well as anti-sense oligonucleotides (oligo) have been developed to 
inhibit C-Raf signaling.  A lipid-encapsulated C-Raf oligo known as LErafAON 
finished phase I studies in 2006, and is currently undergoing further clinical 
development(113).  Sorafenib, the most successful small molecule inhibitor of C-
Raf kinase, was approved by the FDA for renal cell carcinoma.  Upon further 
clinical and preclinical investigation it was found that Sorafenib not only inhibits 
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C-Raf and B-Raf kinase activities, but also VEGF, PDGF, Flt3, c-Kit and FGFR 
signaling(114).  Currently Sorafenib is undergoing further clinical investigation for 
single and combination therapy in hepatocellular carcinoma, non-small cell lung 
cancer, pancreatic cancer, breast cancer, melanoma, and hematological 
malignancies(115).  The success of Sorafenib as a multi-kinase inhibitor has led 
to the approval of Sunitinib, an inhibitor that targets Raf along with VEGF-R, 
PDGF-R and c-Kit signaling.  Sunitinib is currently approved for renal cell 
carcinoma and Imatinib-resistant GIST (gastrointestinal stromal tumors), and is 
now considered the gold standard of care for these diseases.  The success of 
these compounds in the clinic has led to debate as to whether molecularly 
targeted therapies for cancer need to be highly specific or broadly specific.  Due 
to the multi-faceted broad spectrum of proteins inhibited by Sorafenib and 
Sunitinib, it is difficult to determine from this example if blocking Raf kinase 
activity selectively will be beneficial as a mono-therapy for cancer.  However, the 
number of inhibitors presently clinically available has validated targeting the 
Raf/Mek/Erk pathway for cancer, whether at the Raf or Mek level.     
The MAPK cascades continues downstream of Raf activation with Mek 
phosphorylation.  Mek1 and Mek2 belong to a gene family comprised of 5 Mek 
proteins altogether.  Mek1 and 2 are highly homologous, differing only in the 
proline-rich region among the kinase sub-domains 9 and 10(116).   The proline 
rich domain is necessary for Raf binding and activation, and this difference may 
confer substrate specificity for the binding affinity of the different Raf 
isoforms(117).  Mek1 and 2 are also the only known activators of Erk1/2, 
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representing a classic bottleneck in cell signaling.  Several studies have shown 
that constitutive activation of the Mek pathway is associated with different cancer 
types, including hepatocellular carcinoma, renal cell carcinoma, breast cancer, 
squamous cell carcinoma, AML (acute myelogenous leukemia) and CML (chronic 
myelogenous leukemia) (reviewed in (65).  Therefore, Mek kinase activity has 
been a sought-after target for cancer therapy.  The first inhibitors of Mek 
activation were developed in the mid-1990’s.  PD098059 and U-0126 both inhibit 
the activation of Mek, but did not fit the pharmacological profile necessary for 
development.  The lack of solubility and bioavailability prompted the search for 
more Mek inhibitors.  The first Mek inhibitor to demonstrate antitumor efficacy in 
mouse models, and subsequently the first to move to clinical trials, was CI-1040.  
In mouse models CI-1040 inhibited human and mouse colon tumors by as much 
as 80 percent(77).  CI-1040, like PD98059 and U-0126, is noncompetitive with 
ATP.  It binds an allosteric site on Mek, preventing its activation.  Phase I and II 
studies, however, showed that CI-1040 lacked the sufficient antitumor activity, 
metabolic stability, and bioavailability for further development.  Currently there 
are 2 promising Mek inhibitors undergoing phase II clinical trials.  PD-0325901 
and AZD6244 are both orally available, selective Mek inhibitors that are 
noncompetitive with ATP.  Both compounds are well tolerated in the clinic, and 
have been shown to inhibit P-Erk1/2 levels in biopsies of human tumors as well 
as in peripheral blood mononucleocytes (PBMCs).  Dosing with either of the Mek 
inhibitors alone have yet to show objective response, however stable disease 
was reported in 12-28 percent of patients.  Future efforts for developing these 
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Mek inhibitors include combination trials to inhibit other known signaling 
pathways common to cancer progression, such as the PI3K pathway. 
The final step in the MAP kinase pathway is the activation of extra-cellular 
signal-regulated kinase 1 and 2 (Erk1/2), also known as p44 and p42 MAP 
kinases. There has been a positive correlation with overexpression or constitutive 
activation of Erk1/2 in both human tumors and tumor cell lines.  Likewise, 
activation is also involved in many physiologically relevant events such as cell 
motility, proliferation, differentiation, and survival(71, 118, 119).  Erk1/2 have 
been shown to be rapidly phosphorylated downstream of growth factor signaling.  
Activating phosphorylation events by Mek1 and Mek2 have been described on 
threonine 183 and tyrosine 185 (116, 120).  These activating phosphorylation 
events allow Erk1/2 to translocate to the nucleus where they target the 
transcription factors Elk-1, c-Fos, and c-MYC, among others.  These targets are 
thought to be responsible for proliferative effects of Raf/Mek/Erk signaling, as 
they are tied to increasing transcription of cell cycle regulators and DNA 
synthesis machinery.  Aside from translocation to the nucleus, activated Erk1/2 
proteins also activate cytoplasmic signaling modifiers such as microtubule-
associated proteins, ribosomal protein S6 kinase, SHP2, EGFR, SOS, C-Raf and 
Mek(121, 122).  The turnover of phosphorylated Erk proteins is mediated by 
regulatory protein phosphatase that remove the activating phosphate groups 
from the proteins.  Loss of these phosphatases has been described in neoplasia, 
and is currently targeted for therapeutic intervention.  The most characterized 
phosphatases for Erk1/2 is the mitogen-activated protein phosphatase-1 (MKP-
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1).  MKP-1 is a dual-specificity, serum-inducible phosphatase selective for Erk1/2 
over Mek1(123).  Loss of MKP-1 is correlated with increasing grades of prostate, 
colon, and bladder cancer(124, 125).           
In normal cells, the regulation of the MAP kinase pathway is complex.  
While it is well established that the activation of Erk kinases is regulated by 
receptor tyrosine kinases such as EGFR and PDGFR via activation of Ras (64, 
71-73), more recently, adrenergic receptor (AR) stimulation of cAMP has also 
been shown to regulate the activation of Erk1/2 in normal cells (reviewed in (34, 
36, 126, 127)).  For example, in some normal cells such as cardiac myocytes and 
bone cells cAMP was shown to activate Erk1/2, whereas in others such as 
adipocytes and endothelial cells it was shown to inhibit Erk1/2 activation(33, 50, 
59, 128, 129).  The mechanism for the crosstalk between the heterotrimeric G 
proteins and MAP kinase pathway in normal cells is still relatively unclear, with 
many signaling mechanisms proposed depending on cell types.  Activation of the 
β2 AR results in release of the activating subunit Gαs, which stimulates the 
enzyme adenyl cyclase to convert ATP to cAMP.  cAMP is a classic second 
messenger that signals to multiple substrates and controls many physiological 
events.  cAMP activates both protein kinase A (PKA) as well as guanine 
nucleotide exchange factor EPAC1 and 2 (Exchange Proteins Activated by 
cAMP), resulting in two different pathways in which communication with C-Raf 
occurs.  In normal cells, PKA is known to phosphorylate C-Raf on multiple serine 
residues (S43, S259, S233) that inhibit the kinase activity or activation of 
Raf(112).  Likewise, EPAC activation results in GTP-binding and activation of 
 25
Rap1, which can compete with C-Raf for binding sites on Ras.  Ultimately this 
competition results in decreased activation of C-Raf and inhibition of downstream 
MAP kinase signaling.  Alternatively, in astrocytes, thyroid cells, kidney cells and 
megakaryocytic cells it has been shown that cAMP-mediated activation of Rap-1 
can result in activation of B-Raf through Src signaling, leading to increased 
Erk1/2 phosphorylation and cell proliferation(34).  In tumor cells, however, little is 
known about adrenergic receptor regulation of Erk1/2 activation.  In this Chapter 
of the thesis we demonstrate that stimulation of the β2AR induces significant 
tumor growth suppression in human cancers where this stimulation results in the 
inactivation of the C-Raf/Mek1/2/Erk1/2 pathway by a cAMP-dependent 
activation of PKA, but not the Rap1 guanine nucleotide exchange factor EPAC. 
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Materials and Methods 
 
Cell Lines and Transfections 
 
All cell lines used were obtained from American Type Tissue Collection (ATCC), 
(Manassas, VA), or from the DCTD Tumor Repository, (Frederick, MD).  
Propagation was carried out according to ATCC protocols.  Propagation media 
was obtained from Invitrogen Corporation (Carlsbad, CA).  DNA transfections 
were carried out using TransIT-LT1 transfection reagent (Takara Mirus, Madison, 
WI) according to the manufacturer’s protocol.  Briefly, 4x105 MDA-MB-231 cells 
were grown to approximately 70% confluency in medium supplemented with 10% 
FBS (Atlanta Biologicals, Atlanta, GA) in the absence of antibiotics.  For 
transfection, LT1 was pre-incubated in 200 µl per transfection in Opti-MEM 
(Invitrogen) for 20 minutes prior to addition of plasmid.  2 µg of plasmid DNA 
(pFC-Mek  Stratagene, La Jolla, CA) per transfection was incubated with the 
Opti-MEM/LT1 mixture for 20 minutes after which the transfection mixture was 
added to cells and incubated at 37°C for 48 hours.  At that time, cells were then 
treated with either DMSO or ARA-211 (10µM) for 48 hours and subsequently 
assayed for proliferation via Alamar Blue metabolism and harvested for western 
blot analysis as described below.     
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Cytoblot Screening for Small Molecules that Decrease Phospho-Erk1/2  
 
MDA-MB-231 cells were plated into sterile, white opaque, 96 well tissue culture 
plates at a density of 25,000 cells/well, cells were allowed to attach overnight and 
were treated for 1 hour in the presence of either vehicle control, 20 µM PD-98059 
(EMD Biosciences, San Diego, CA), or 10 µM of NCI Diversity Set of 2000 
compounds (1compound/well) (http://dtp.nci.nih.gov/) as described by us (78).  
Cells were then washed, fixed for one hour at 4oC cold 3.7% formaldehyde and 
permeabilized for 5-min with ice-cold methanol.  Cells were washed, and rocked 
overnight at 4oC with anti-phospho-p44/42 MAPK (Cell Signaling Technology, 
Beverly, MA) and Horse Radish Peroxidase conjugated anti-Rabbit IgG 
secondary antibody (Jackson ImmunoResearch, West Grove, PA).  The plates 
were washed and chemiluminescence reagent added to the wells of the plates, 
then x-ray film directly placed on top of the plates.  Quantification of the results 
was done using a GS-700 scanning densitometer (Bio-Rad Laboratories, 
Hercules, CA). 
 
Western Blotting 
 
Treated cell samples were lysed in 30 mM HEPES, 10 mM NaCl, 5 mM MgCl2, 
25 mM NaF, 1 mM EGTA, 1% Triton-X-100, 10% Glycerol, 2 mM Sodium 
orthovanidate, 10 µg/mL aprotinin, 10 µg/mL soybean trypsin inhibitor, 25µg/mL 
leupeptin, 2 mM phenylmethylsulfonylfluoride (PMSF), 6.4 mg/mL p-
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nitrophenylphosphate for 30 minutes at 4oC, and proteins run on SDS-PAGE gels 
then transferred to nitrocellulose membranes.    Membranes were blocked in 
either 5% milk in PBS, pH 7.4, containing 0.1% Tween-20 (PBS-T) or 1% BSA in 
TBS, pH 7.5, containing 0.1% Tween-20 (TBS-T).  Phospho-STAT3 and 
phospho--AKT antibodies were diluted in 1% BSA in TBS-T while phospho-C-
Raf, phospho-Mek, and phospho-p44/p42 MAPK antibodies (Cell Signaling) were 
diluted in 5% milk in PBS-T for either 1 hour at room temperature or overnight at 
4oC.  HRP-conjugated secondary antibodies (Jackson ImmunoResearch, West 
Grove, PA) were diluted in 5% milk in PBS-T or TBS-T at a 1:1000 dilution for 
one hour at room temperature.  Western blots results were visualized using 
enhanced chemiluminescence.  Stripping of the membranes for reblotting was 
done using stripping buffer (62.5 mM Tris pH 7.6, 2% SDS, 0.7% 2-
mercaptoethanol) at 500C for 30 minutes.  Cells treated with ARA-211, 8CPT-2′-
O-Me-cAMP, H89 and Forskolin to determine effects on P-Erk 1/2 and other 
signaling events by Western blot were treated for one hour at varying doses.  
Pre-treatment with H89 was done for 15 minutes followed by 45 minutes of ARA-
211 treatment. 
 
In Vitro Kinase Assays 
 
MDA-MB-231 cells (2x106) were lysed for 30 minutes at 4oC in RIPA-150 buffer 
(10 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM EDTA, 1% Triton X-100, 
.1% SDS, 100 µM sodium orthovanadate, 1 µM aprotinin, 10 µM leupeptin, 10 
 29
µM antipain).  Cell debris was pelleted at 13000 rpm for 15 minutes at 4oC and 
the lysate was rocked overnight with 10 µg of either C-Raf or Mek antibodies 
(Santa Cruz Biotechnologies, Santa Cruz, CA).  25 µl of protein A/G PLUS 
agarose (Santa Cruz Biotechnology) was then added and rocked for 4 hours at 
4oC.  Samples were spun at 2000 rpm for 5 minutes to collect the agarose 
beads, which were then washed four times with lysis buffer.  On the final wash 
each pellet was divided into 5.  Pellets were re-suspended in 30 µl kinase buffer 
(30 mM HEPES, pH 7.5, 7 mM MnCl2, 5 mM MgCl2, 1 mM dithiothreitol and 15 
µM adenosine triphosphate (ATP) with either 10 µM U-0126 (EMD Biosciences) 
ARA-211, Raf Kinase Inhibitor (EMD Biosciences), or DMSO vehicle control.  
Finally, 0.5 µg Mek1 or ERK-2 peptide substrate (Upstate Biotechnologies, Lake 
Placid, NY) was added, followed by 20 µCi [γ-32P]-ATP per sample.  Samples 
were then incubated at room temperature for 30 minutes and the reaction 
terminated by the addition of 30µl 4x SDS-PAGE sample buffer (33% glycerol, 
0.3 M DTT, 6.7% SDS, 15% β-mercaptoethanol, 0.1% bromphenol blue), which 
was then boiled at 100oC for 5 minutes.  Samples were run on a 10% 
polyacrylamide gel to separate proteins; gels were dried and phosphorylation 
results visualized via autoradiography.      
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In Vivo Kinase Assay 
 
Intact MDA-MB-231 cells (2x106) were treated either with vehicle control 
(DMSO), 10 µM U-0126, 10µΜ Raf Kinase Inhibitor, or 10µΜ ARA-211.  
Samples were then processed for kinase assays as described above. 
 
MTT Assay  
 
2000 cells per well were plated into 96 well tissue culture plates, and the cells 
were allowed to attach overnight at 37oC with 10% CO2.  Cells were then treated 
with increasing concentrations of ARA-211, Forskolin (Sigma-Aldrich, St. Louis, 
MO) or vehicle (DMSO) and incubated for four days.  At that time treatment 
medium was removed and replaced with 100 µl of 1mg/ml MTT (Sigma-Aldrich) 
in media and incubated at 37oC, 10% CO2 for 3 hours.  After 3 hours the MTT 
media was removed and replaced with 100 µl/well of DMSO, rocked at room 
temperature for 5 minutes, then absorbance read at 540 nm on a micro-plate 
reader. 
 
Alamar Blue Proliferation Assay 
 
For proliferation assays using exogenous constitutively activated Mek or the 
β2AR antagonist ICI-118.551, Alamar Blue metabolism assay used to determine 
cell viability according to the manufacturers protocol (Biosource, Camarillo, CA).  
Briefly, cells were treated and grown as described above; Alamar Blue was 
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added to the media at a 1:10 dilution and incubated for 3 hours.  Media/Alamar 
Blue was removed from the cells and aliquoted into 96 well plates (100µl per 
well) and fluorescence read on a Wallac Victor 2 plate reader at excitation 
540nM, and emission 615nM.   
 
 
Soft Agar Assay 
 
Anchorage independent growth assays were performed as previously described 
(85).  Briefly, agar was diluted to 0.3% in propagation media containing 20,000 
cells and either vehicle or ARA-211 and 1ml of cell/agar mixture plated on top of 
2ml of a 0.6% layer of agar in medium alone.  Cells were grown for three to four 
weeks at 37°C, 10% Co2 and were fed weekly with 100µl per well of 
media/treatment.  Quantification of colonies was done using a GS-700 scanning 
densitometer. 
 
Apoptosis Assay 
 
Apoptosis was analyzed using the Cell Death Detection ELISA (Roche, 
Indianapolis, IN) measuring cytoplasmic histone-associated mono- and 
oligonucleosome DNA fragments.  Procedures were carried out according to the 
manufacturers protocol.  Briefly, 1x105 cells were plated in 60mm dishes and 
treated with various doses of ARA-211 or vehicle for 48 hours.  Cells were lysed 
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with the provided lysis buffer and lysate was incubated on the ELISA plate for 1 
hour to capture the histone associated DNA indicative of apoptotic cells.  Anti-
DNA peroxidase conjugated antibody was added to detect the cleaved DNA and 
the microplate was washed and developed with ABTS substrate which was 
quantitated by microplate reader at 405nm. 
 
 
Total cellular cAMP Measurement 
 
The measurement of total cellular cAMP was done using a cAMP Biotrak ™ 
Enzyme immunoassay (EIA) system (Amersham Biosciences, Piscataway, NJ ) 
according to the manufacturer’s protocol.  Briefly, 2000 cells were plated into 
each well of a 96 well plate.  The next day cells were treated with increasing 
concentrations of ARA-211 or with vehicle for one hour.  Alternatively, MDA-MB-
231 cells were pretreated with antagonists to the α1 (Prazosin, Sigma), α2 
(Yohimbine, Sigma), β1 (Metoprolol, Sigma), and β2 (ICI 118.551, Sigma) 
adrenergic receptors at 100nM for 15 minutes followed by treatment with 10µM 
ARA-211 for 45 minutes.  Cells were then lysed directly in the wells using the 
supplied lysis buffer.  The lysate was transferred to a 96-well cAMP ELISA plate, 
and results were quantified using a Wallac Victor 2 plate reader.   
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PKA Kinase Assay 
 
PKA kinase assays were performed with the SignaTECT® cAMP-Dependent 
Protein Kinase (PKA) Assay System (Promega, Madison WI) according to the 
manufacturer’s protocol.  Briefly, cells were plated (5X106) into 100 mm dishes 
and treated the next day with ARA-211, H-89 (EMD Biosciences), or vehicle for 
one hour.  When pre-treating cells, H89 was dosed for 15 minutes following ARA-
211 treatment for 45 minutes.  Cells were lysed using a Dounce homogenizor 
and lysates were incubated in the supplied kinase reaction buffer, with 32P-ATP 
and biotin labeled PKA peptide substrate for 5 min at 37oC.  Once the reactions 
were quenched they were spotted onto streptavidin membranes and 32P-ATP 
transfer was measured via scintillation counter. 
 
Antitumor Activity in Nude Mouse Xenograft Models 
 
Female athymic nude (nu/nu) mice, 5-6 weeks old, were purchased from Charles 
River (Wilmington, MA) and allowed to acclimate in the animal facility for one 
week. After harvesting, A-549, SNB-19, ACHN, and HCT-116 cells were, 
resuspended in sterile PBS, and injected s.c. into the right and left flanks (10x106 
cells per flank) of the mice as previously described (130).  For MDA-MB-231, 
cells were harvested and resuspended in PBS (10x106 cells per 50 µl) and an 
equal volume of Matrigel (BD Biosciences, San Jose, CA).  100 µl of MDA-MB-
231 cells in PBS/Matrigel were injected s.c. into the mammary fat pads between 
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the 2nd and 3rd nipples on each side of the mice.  Once the tumors reached 
approximately 200-300 mm3 the mice were randomized and treated i.p. with 
0.1ml vehicle (PBS) or ARA-211.  Each treatment group consisted of five mice (2 
tumors per mouse, a total of 10 tumors).  The tumor volumes were determined by 
measuring the length (l) and width (w) and calculating the volume (V=w2l/2).  
Statistical significance between the control and treated animals was determined 
using a student’s t test. 
 
Immunohistochemisty (IHC) and Slide Quantitation 
 
Upon completion of the xenograft study, mice were euthanized and the tumors 
were removed and fixed in 10% buffered formalin for at least 24 hours.  Three 
tumors per treatment group were then prepared and stained for proliferation 
marker Ki-67, apoptosis by TUNEL, and phosphor-Erk1/2 as previously 
described(131).  The IHC slides were analyzed at the Analytical Microscopy Core 
facility of the H. Lee Moffitt Cancer Center & Research Institute.  The Ariol SL-50 
automated image analysis system (Applied Imaging, Santa Clara, CA) was used 
for quantitation of each slide as previously described(132).  Briefly, high-
resolution digital pictures were taken of the entire stained area of each slice of 
tumor tissue for automatic staining quantitation.  Two thresholds were used to 
signify positive staining, one recognizing background and one recognizing 
positive brown staining.  The percentage of positive staining was calculated by 
dividing the positive staining by the total staining (positive + negative) divided by 
 35
the total area stained, and the intensity of the stain was determined by 
calculating the integrated optical density of the positive stain with the negative 
background stain subtracted out.  Each slide analyzed consisted of 54,000 to 
160,000 cells analyzed depending on the size of the tumor when resected.  
Significance of the quantitation was analyzed by a two-tailed student’s t-test.   
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Results 
 
Identification of ARA-211, a selective suppressor of P-Erk1/2 levels in MDA-
MB-231 breast cancer cells.   
 
Many common genetic alterations in human cancers result in the 
hyperactivation of the Mek1/2 kinases leading to constitutively phosphorylated 
Erk1/2(64, 71-73).  Because aberrant activation of the Mek1/2/Erk1/2 pathway 
has been implicated in oncogenesis and tumor survival, we sought to identify 
molecules that thwart this pathway.  To this end, we first used a chemical biology 
approach by screening a 2,000 small molecule compound library (NCI diversity 
set, http://dtp.nci.nih.gov/) from the National Cancer Institute for pharmacological 
agents capable of suppressing the high levels of P-Erk1/2 in the human breast 
cancer cell line MDA-MB-231.  Treatment of MDA-MB-231 cells with compounds 
from the NCI diversity set (96 well plate assay (25 plates total), 1 compound per 
well – see Figure 4) and subsequently processing the plates for a cytoblot using 
an antibody specific for P- Erk1/2, resulted in several compounds that suppress 
P- Erk1/2 levels.  PD-98059, a Mek kinase inhibitor was used as a positive 
control for inhibition of Erk1/2 phosphorylation.  MDA-MB-231 cells were treated 
with the hits from the assay to confirm the anti-P-Erk1/2 activity.  Three 
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compounds from the screen were identified as inhibitors of Erk activation (Table 
1). The IC50 for each compound was obtained from dose response treatment on 
231 cells, resulting in IC50 values of 8, 10, and 500 nM for inhibition of Erk1/2 
phosphorylation (Table 2).  ARA-211 also suppressed P-Mek1/2 levels but not P-
C-Raf, P-JNK, P-p38, P-Akt or P-STAT3 (Figure 5).  These results demonstrated 
that ARA-211 is selective for disrupting the Mek1/2/Erk1/2, but not other 
oncogenic and tumor survival pathways.  
 
 
  
PD-98059
Unconfirmed Hit
Vehicle ARA-211
Figure 4.  High throughput screening of the NCI Diversity Set by cytoblot
analysis reveals three inhibitors of Erk1/2 activation
Figure 4. High throughput screening identifies ARA-211.  MDA-MB-231 cells 
were plated in twenty-five 96-well plates, treated with vehicle (8 wells), PD-
98059 (2 wells) or 2000 compounds (1 compound/well) from the NCI diversity 
set, and the plates processed for immunocytoblotting with an anti-phospho-
Erk1/2 antibody as described under Materials and Methods.  Plate #23 is 
shown with wells treated with vehicle as well as those treated with the Mek
inhibitor PO98059. 
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Table 1.  Chemical structures of the compounds identified from  the NCI 
Diversity Set as inhibitors of P-Erk1/2 levels
Table 1.  Cytoblot screen reveals three structurally similar chemical 
compounds that lower anti-P-Erk1/2 levels.
OH
N
H OH
O H
N
OH
N
H
OH
OH
H
H
O    
O N
H
S
NSC #: 289336 NSC #: 355078 NSC #: 39215
Plate #: ERKi-2067
ARA-67
Plate #: ERKi-23211
ARA-211
Plate #: ERKi-624
ARA-624
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0      10
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Figure 5.  ARA-family of compounds selectively inhibit P-Erk1/2 levels 
in MDA-MB-231 breast cancer cells
Figure 5.  Validation of ARA-211 as selective suppressor of P-Erk1/2 levels in 
MDA-MB-231 breast cancer cells. ARA-211 treatment of MDA-MB-231 cells 
and Western blotting were performed as described under Materials and 
Methods, and resulted in suppression of P-Erk1/2 and P-Mek1/2 but not C-
Raf, P-JNK, P-p38, P-Akt and P-STAT3 levels. 
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 The fact that ARA-211 suppressed the levels of P-Mek1/2 and P- Erk1/2 
suggested that it might be a C-Raf kinase inhibitor.  In-vitro incubation of C-Raf 
and Mek1, immunoprecipitated from MDA-MB-231 cells, with ARA-211 did not 
inhibit C-Raf and Mek1 kinase activities (Figure 6).  As expected, the C-Raf 
kinase inhibitor (Rki, Calbiochem) and the Mek1 inhibitor (U-0126, EMD 
Biosciences, San Diego, CA) blocked C-Raf and Mek1 kinase activities in vitro, 
respectively (Figure 6).  In contrast to the in vitro studies, C-Raf and Mek1 kinase 
activities were blocked by ARA-211 when intact MDA-MB-231 cells were first 
treated with ARA-211, prior to cell lysis and immunoprecipitation of C-Raf and 
Mek1 (Figure 6).  As expected only Rki but not U-0126 inhibited C-Raf kinase 
whereas both Rki and U-0126 inhibited Mek1 kinase when whole cells were 
treated.  Contrary to the effects on C-Raf kinase activity, B-Raf kinase activity 
was not affected upon stimulation of cells with ARA-211. 
P-Mek-1
C     RKi   211
P-Erk-2
C         U      211
P-Mek-1
C     Rki    U    211   
IP Raf-1
P-Erk-2
C    Rki    U    211       
IP Mek-1
IP Raf-1 IP Mek-1
IP B-Raf
P-Mek-1
C       211         Iso         U        Rki     
Figure 6.  Raf-1, but not B-Raf, kinase activity is inhibited upon ARA-211 
treatment of whole cells, but not in vitro. A.  Raf-1 and Mek-1 were 
immunoprecipitated from MDA-MB-231 cells and treated in vitro with ARA-
211, Rki or U-0126 and kinase assays followed by SDS-PAGE were 
performed as described in Materials and Methods.  B. and C. Intact cells 
were first treated with ARA-211, then C-Raf and Mek-1 (B.) and B-Raf (C.) 
were immunoprecipitated and processed as for A.  Only in cells treated with 
ARA-211 is Raf-1 kinase inhibited.   In vitro only the Raf kinase inhibitor (RKi) 
and Mek kinase inhibitor (U-0126) blocked MAPK signaling. 
Figure 6.  C-Raf, but not B-Raf, kinase activity is inhibited upon ARA-
211 treatment of whole cells, but not in-vitro
A.
B.
C.
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ARA-211 is a selective β2 adrenergic receptor agonist that inhibits P-Erk 
1/2 levels by increasing cAMP 
 
The fact that ARA-211 inhibits C-Raf and Mek1 kinase activities when 
intact cells are treated but not in vitro suggested that the target for this compound 
is upstream of C-Raf kinase.  A chemical similarity search identified ARA-211 as 
pirbuterol, and resulted in many analogues of the beta adrenergic receptor 
agonist family.  Table 2 depicts structural analogues of the ARA compounds that 
were located using SciFi-Scholar, a program linked to the American Chemistry 
Society registry of chemical compounds.  The commercially available compounds 
were ordered and first screened at 10µM for inhibition of activation of Erk1/2 in 
MDA-MB-231 cells.  Epinephrine, Isoproterenol, and Adrenalone showed 
inhibition of ERK 1/2 activation; while 2,6-Lutidine-α,3-diol, 1-(6-(1-Hydroxy-
ethyl)-Pyridin-2-Yl)-Ethanol, and 3-Hydroxy-2,6-Pyridinedimethanol-HCl did not 
inhibit the activation of ERK 1/2 in MDA-MB-231 cells.  The active compounds 
were then tested in MDA-MB-231 cells in a dose response manner to better 
characterize each compound.   IC50 values of epinephrine and adrenalone were 
found to be 5 and 10nM respectively, while Isoproterenol demonstrated an IC50 
of .01 nM (Table 2). Comparing ARA-211 with 2,6-Lutidine-α,3-diol & 3-Hydroxy-
2,6 Pyridinedimethanol-HCl it can be determined that the tertiary butyl amine 
group is critical to ARA-211 activity.  However, the size of this group appears to 
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be important as well, with the isopropyl (isoproterenol) being better than the 
methyl (epinephrine).  It can also be determined, by comparing ARA 211 to 
epinephrine and isoproterenol that the cyclic nitrogen is not significant.  Finally, 
the aliphatic hydroxyl is critical as its replacement with S-methyl results in loss of 
the ability to lower P-Erk1/2 levels (compare ARA-624 to epinephrine).  The main 
value from the SAR however, was the crucial information that led us to 
investigate stimulation of the β2 AR as an event leading to the inhibition of P-
Erk1/2 in MDA-MB-231 cells.  Based on the chemical structure search we found 
that the hit that was identified as ARA-211 is pirbuterol, a selective β2 AR 
agonist.  
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Table 2.  Structure-activity relationship studies identify the ARA family 
of inhibitors as analogues of epinephrine, and identifies ARA-211 as 
pirbuterol
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To demonstrate that ARA-211 acts as a β2 adrenergic receptor agonist in 
MDA-MB-231 cells, and that this results in blockade of the Raf/Mek/Erk pathway, 
we treated these cells with ARA-211 and first showed that this compound 
induced the formation of cAMP (Figure 7).  We then determined that ARA-211 is 
highly selective for β2 adrenergic receptors by determining that only β2 but not 
β1, α1 or α2 receptor antagonists block the ability of ARA-211 to induce cAMP 
formation (Figure 7).  Furthermore, we used isopreterenol, another selective 
adrenergic receptor agonist and showed that it also stimulates the formation of 
cAMP and decreases the levels of P-Erk 1/2 (data not shown).  Finally, to 
validate the effects of cAMP signaling on P-Erk1/2 activation MDA-MB-231 cells 
were pretreated with selective adrenergic antagonists followed by ARA-211 
treatment.  ARA-211 mediated inhibition of P-Erk1/2 levels was abrogated only 
when β2 adrenergic signaling was blocked (Figure 8). Treatment of MDA-MB-231 
cells with a β1 selective, dobutamine, and a β3 selective agonist CI316243, did 
not inhibit P-Erk 1/2 levels (data not shown).   Furthermore, to demonstrate that 
the effects of P-Erk1/2 inhibition was due to cAMP mediated signaling we 
stimulated adenyl cyclase to produce cAMP directly by forskolin treatment.  
Forskolin inhibited P-Erk1/2 levels with an IC50 of 10 nM, similar to the ARA-211 
induced inhibition (Figure 8).  Taken together these data demonstrate that ARA-
211 is a β2-selective adrenergic receptor agonist that suppresses P-Erk1/2 by 
increasing cAMP levels.   
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Figure 7.  ARA-211 stimulates cAMP selectively through β2 adrenergic 
receptor activation
Figure 7.  ARA-211 is a selective β2 adrenergic receptor agonist.  MDA-MB-
231 cells were treated with ARA-211 alone or in the presence of β1, β2, α1 or 
α2 adrenergic receptor antagonists and the levels of cAMP were determined 
as described under Materials and Methods.  Only pre-treatment with a β2 
selective adrenergic receptor antagonist blocked the ability of ARA-211 to 
stimulate cAMP in MDA-MB-231 cells.
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 ARA-211 (10µM)        - +     - - - - +     +     +    +    
β2 antagonist (nM)   0     0    1     10   50  100  1    10    50  100 
P-Erk1/2
Erk1/2
P-Erk1/2
Erk1/2
Forskolin (nM)    0         0       1      10     50    100 
ARA-211 (10µM)       - +        - - - -
Figure 8.  ARA-211-mediated cAMP stimulation through β2 adrenergic 
receptor activation results in inhibition of P-Erk1/2
Figure 8.  ARA-211 is a selective β2 adrenergic receptor agonist that inhibits 
P-Erk 1/2 levels by increasing cAMP. A. MDA-MB-231 cells were treated with 
ARA-211 alone or in the presence of β1, β2, α1 or α2 adrenergic receptor 
antagonists and the levels of P-Erk1/2 were determined as described under 
Materials and Methods. B. Similarly, direct activation of cAMP by forskolin
also results in inhibition of P-Erk1/2 activation.
B.
A.
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ARA-211 inhibits P-Erk 1/2 levels by PKA but not EPAC activation 
 
The data from Figures 7 and 8 demonstrated that ARA-211 stimulates the 
production of cAMP, which in turn suppresses the C-Raf/Mek1/2/Erk1/2 pathway.  
Previous studies primarily in normal cells have shown that the Ras-Erk pathway 
can be regulated by the ability of cAMP and PKA to modulate growth factor 
signaling via C-Raf and B-Raf.  PKA, which is activated by cAMP, has been 
shown in some normal cells to interfere with Ras-C-Raf binding, downregulating 
MAPK-Erk signaling.  This occurs through the PKA-dependant activation of the 
small G-protein Rap-1.  Rap-1 competes with C-Raf for binding to GTP-Ras, 
resulting in a smaller amount of activated C-Raf available to activate Mek1/2.  
Alternatively, Rap1 can be activated by cAMP independently of PKA.  Exchange 
Proteins Activated by cAMP (EPACs) are guanosine nucleotide exchange factors 
(GEFs) that are activated by cAMP and modulate the GTP loading of Rap1.  
Other studies have shown that if a cell line expresses high levels of B-Raf that 
PKA can activate B-Raf in a Ras-independent fashion.  Active B-Raf is then free 
to phosphorylate and activate Mek-2, which activates Erk1/2.  Therefore, the 
ARA-211 cAMP-dependent decrease in P-Erk1/2 levels could be modulated by 
cAMP-activation of either PKA or EPAC.  In addition, PKA could either inactivate 
C-Raf directly, or through activation of Rap-1.  Based on these possibilities, we 
next examined whether cAMP suppresses the P-Erk1/2 levels by activating the 
protein kinase A (PKA) or by activating the Rap1 guanine exchange factor EPAC.  
To this end, we treated MDA-MB-231 cells either with the EPAC activator 8-CPT-
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2′-O-Me-cAMP, which would mimic the effects of ARA-211 on P-Erk1/2 levels, or 
the PKA kinase inhibitor H-89, which would block the effects of ARA-211.  Figure 
9 demonstrates that treatment with the EPAC activator did not affect P-Erk1/2 
levels.  In contrast, treatment with the PKA inhibitor prevented ARA-211 from 
suppressing the levels of P-Erk1/2.  These results suggest that ARA-211-induced 
decrease in p-Erk1/2 levels is mediated through a cAMP-dependent PKA 
activation, but not a cAMP-activation of EPAC.  If this is the mechanism involved 
then ARA-211 would be expected to activate PKA, and PKA siRNA would be 
expected to inhibit ARA-211 from decreasing the P-Erk1/2 levels.  Therefore, to 
further strengthen this suggestion, we first determined if ARA-211 is able to 
activate PKA.  Figure 10 shows that ARA-211 treatment of MDA-MB-231 cells 
activated PKA kinase activity, and that H-89 prevented ARA-211 from activating 
PKA.  siRNA to the alpha catalytic subunit of PKA was then used to further 
validate the necessity of PKA activation for ARA-211 mediated inhibition of 
Erk1/2 phosphorylation.  Figure 10 demonstrates that as PKA protein levels are 
diminished the effects of ARA-211 on P-Erk1/2 are rescued.  A dose response of 
PKA α-cat siRNA of 5, 50 and 100 nM were used to demonstrate a linear 
signaling correlation between PKA α catalytic subunit protein levels and P-Erk1/2 
phosphorylation.    
  
 P-Erk1/2
Erk1/2
ARA-211 (10µM)     - +      - - - - - - - -
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Figure 9.  ARA-211-mediated cAMP stimulation (through β2 adrenergic 
receptor activation) results in inhibition of P-Erk1/2 through PKA 
activation, not EPAC activation of Rap1
Figure 9.  ARA-211 inhibits P-Erk1/2 levels by PKA but not EPAC activation. 
MDA-MB-231 cells were treated either with ARA-211, the EPAC activator 
8CPT-2′-O-Me-cAMP (A.), the PKA inhbitor H-89 (B.), or ARA-211 and H-89  
(B.).  Direct activation of EPAC did not inhibit P-Erk1/2 levels, while blockade 
of PKA kinase activity by H89 abrogated ARA-211-mediated inhibition of P-
Erk1/2
A.
B.
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Figure 10.  ARA-211 inhibits P-Erk1/2 levels by PKA but not EPAC activation. 
A. PKA kinase assays show ARA-211 stimulates PKA, which is blocked by 
pre-treatment with a β2 antagonist as well as PKA kinase inhibitor H89.  B. 
siRNA to PKA demonstrates that as PKA expression decreases the ability of 
ARA-211 to inhibit P-Erk1/2 levels also diminishes.
Figure 10.  siRNA and kinase assays validate that ARA-211-mediated 
cAMP stimulation results in inhibition of P-Erk1/2 through PKA 
activation
A.
B.
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ARA-211 inhibits tumor cell proliferation by β2AR-stimulation of cAMP and 
inhibition of Mek1/2 
 
The data from the previous figures demonstrated that stimulation of the β2 
AR with ARA-211 suppresses the C-Raf/Mek1/2/Erk1/2 pathway by a cAMP-
dependent activation of PKA but not EPAC.  Whether stimulation of the β2 AR 
and subsequent inhibition of Raf/Mek/Erk causes tumor suppression is not 
known.  Therefore, we next determined whether activation of the β2 adrenergic 
receptor, which leads to inhibition of the C-Raf/Mek1/2/ Erk1/2 pathway, results 
in inhibition of tumor cell growth and survival of human cancer cells.  Figure 11 
demonstrates that ARA-211 inhibits the proliferation of MDA-MB-231 cells in a 
dose dependent manner, and requires the ability of ARA-211 to bind the β2 
adrenergic receptor.  MTT and Alamar Blue assays were used to determine the 
effects of ARA-211 on cell proliferation.  The proliferation of cells that were 
pretreated with β2 AR antagonist was not affected by ARA-211, in contrast to cell 
treated with ARA-211 alone.  Western blotting from cells from the Alamar Blue 
proliferation assay demonstrated that pre-treatment with the β2 AR antagonist 
rescued from the ARA-211 induced inhibition of Erk1/2 phosphorylation (Figure 
11).  Likewise, forskolin was used to directly stimulate adenyl cyclase to 
determine if β2 AR stimulation resulting in cAMP production is a necessary step 
in the inhibition of cell proliferation.  Figure 12 shows that forskolin indeed inhibits 
MDA-MB-231 cell proliferation with an IC50 of approximately 50 nM. 
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Figure 11.  ARA-211 inhibition of  MDA-MB-231 cell proliferation 
requires β2 AR activation and inhibition of P-Erk1/2
Figure 11.  ARA-211 inhibition of MDA-MB-231 cell proliferation requires β2 
AR activation and inhibition of P-Erk1/2. MDA-MB-231 cells were treated with 
ARA-211 alone (square) or in the presence of the β2AR antagonist ICI 
118.551 (triangle) and the effects of treatment on tumor cell growth (A.) and 
P-Erk1/2 levels (B.) were determined as described under Materials and 
Methods.  
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Figure 12.  Direct activation of adenylyl cyclase by forskolin inhibits the 
proliferation of MDA-MB-231 cells
Figure 12.  Forskolin inhibits MDA-MB-231 cell proliferation correlating with 
inhibition of P-Erk1/2.  MDA-MB-231 cells were treated with vehicle (square) 
or Forskolin (triangle) and the effects on tumor cell growth determined.
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The above data clearly demonstrated that the ability of ARA-211 to disrupt the C-
Raf/Mek1/2/Erk1/2 pathway and to inhibit tumor cell growth and survival depends 
on its ability to stimulate the β2 adrenergic receptor and produce cAMP.  
However, the ability of ARA-211 to inhibit tumor cell growth could be due to its 
ability to affect cellular events other than those leading to decreased P-Erk1/2.  
Therefore, we next determined whether the inhibition of tumor cell growth by 
ARA-211 requires its ability to inhibit the C-Raf/Mek1/2/Erk1/2 pathway.  We 
reasoned that if suppression of C-Raf and Mek1/2 were critical to ARA-211 
inhibition of tumor growth then ectopically expressing constitutively active Mek1/2 
would rescue human cancer cells from the effects of ARA-211.  Figure 13 shows 
that MDA-MB-231 cells that ectopically express constitutively active Mek1/2 (CA-
Mek) are resistant to ARA-211 inhibition of P- Erk1/2 and inhibition of tumor cell 
growth.  Mek1/2 levels clearly show a dramatic induction of expression with 
transfection of CA-Mek plasmid.  Likewise, downstream signaling through Erk1/2 
activation is also increased.  Finally, P-Erk1/2 inhibition mediated by ARA-211 is 
rescued in the cells over expressing CA-Mek.  This demonstrates that ARA-211 
inhibits proliferation of MDA-MB-231 cells through inhibition of Mek/Erk signaling.     
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Figure 13.  ARA-211-mediated inhibition of MDA-MB-231 cell 
proliferation is dependent on the ability to inhibit Mek1/2 and to 
decrease P-Erk1/2 levels
Figure 13.  Inhibition of proliferation by ARA-211 is dependent on 
Mek1/2/Erk1/2 signaling.  MDA-MB-231 cells were treated with ARA-211 
alone (open square) or in the presence of CA-Mek (closed square) and the 
effects of treatment on tumor cell growth (A.) and P-Erk1/2 levels (B.) were 
determined as described under Materials and Methods.
A.
B.
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Screening of NCI 60 cell  line panel leads to discovery of ARA-211 sensitive 
and insensitive cell lines 
 
So far we have demonstrated that ARA-211 binds the β2 AR, stimulates 
cAMP, and inhibits Erk1/2 phosphorylation through a PKA dependent mechanism 
leading to inhibition of cell proliferation in MDA-MB-231 cells.  While these 
findings have not been reported previously and therefore are novel, it is critical 
that we determine whether this mechanism of tumor suppression is relevant to 
other human tumors, or if it is unique to the MDA-MB-231 breast cancer cell line.  
To this end we searched for cancer cell lines that possess the correct signaling 
circuitry to respond to β2 AR stimulation similarly to the MDA-MB-231 cell line.    
We hypothesized that cells that express the β2 AR and high levels of P-Erk1/2 
would be candidates for ARA-211 sensitivity based on the necessity of ARA-211 
to bind the β2 AR and inhibit P-Erk1/2 to block cell proliferation.  Likewise, 
literature reports suggest that in some normal cells the ratio of C-Raf to B-Raf 
expression levels may dictate whether β2 AR activation inhibits or activates 
Erk1/2.  To reach our goal we determined by western blotting the levels of β2 AR, 
P-Erk1/2, C-Raf and B-Raf in the lysates from the NCI 60 cell line panel.  Table 3 
summarizes the findings from the western blot analysis shown in Figure 14.  A 
minus (-) sign indicates little to no expression, a plus (+) sign indicates moderate 
expression, whereas a double plus (++) sign indicates high protein expression 
(Table 3).  Based on the expression analysis, the cell lines that were available 
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and expressed both the β2 AR and P-Erk1/2 were tested for ARA-211 sensitivity.  
Cells insensitive to treatment based on the ability of ARA-211 to inhibit P-Erk1/2 
were denoted by a *, and the cell lines tested that were sensitive to ARA-211 
treatment were denoted by a **.  Out of 20 lines tested 3, MDA-MB-231, ACHN, 
and SF-539, were found to be sensitive to ARA-211 treatment.  Analysis of the 
findings from the cell lines tested with ARA-211 compared to C-Raf and B-Raf 
expression led to the finding that the ratio hypothesis did not hold true.  No cell 
lines tested demonstrated an ARA-211 mediated increase in P-Erk1/2 
expression, even when expression of B-Raf was high and C-Raf was low.  
Similarly, it was found that even though some cells express β2 AR, P-Erk1/2, and 
C-Raf but not B-Raf, the cells were still insensitive to ARA-211 treatment (IGR-
OV1, MCF-7, Table 3, Figure 14).  It is clear however, that all cell lines that 
responded to ARA-211 express β2 AR and have high levels of P-Erk1/2.  
Therefore, the sensitive cell lines MDA-MB-231, SF-539, and ACHN, along with 
insensitive cell lines A549, HCT-116, and SNB-19 were chosen to provide a 
panel of cell lines to demonstrate that only cells where ARA-211 stimulates 
cAMP production (which results in decreased levels of P-Erk1/2) are sensitive to 
ARA-211-induced apoptosis and human tumor suppression. 
 Table 3.  ARA-211 sensitive and insensitive cell lines tested from the 
NCI 60 cell line panel do not correlate with C-Raf and B-Raf expression 
levels
Origin Gel # Cell Line β2-AR pErk ½ C-Raf B-Raf 
Colon 1 *Colo-205 - + - - 
 2 HCC-2998 - - - + 
 3 HCT-15 + - + + 
 4 *HCT-116 ++ ++ ++ + 
 5 *HT29 ++ - ++ ++ 
 6 KM 12 ++ - ++ + 
 7 *SW-620 ++ + ++ - 
CNS 8 SF-268 ++ + ++ - 
 9 SF-295 ++ - ++ - 
 10 **SF-539 + ++ + + 
 11 *SNB-19 + + ++ - 
 12 SNB-75 + + + ++ 
 13 *U251 + ++ + ++ 
Leukemia 14 CCRF-CEM - - + - 
 15 HL-60 ++ ++ - ++ 
 16 K562 ++ - ++ ++ 
 17 MOLT4     
 18 RPMI-8226 - - - - 
 19 SR ++ - ++ + 
Lung 20 *A549 + + ++ - 
 21 *EKVX ++ ++ - - 
 22 HOP-62 - - + + 
 23 HOP-92 ++ + + - 
 24 NCI-H23 - ++ + ++ 
 25 NCI-H226 - - - ++ 
 26 NCI-H322M - ++ - - 
 27 NCI-H460 - - - + 
Mammary 29 *MCF7 + + + - 
 30 MCF7-Adr Res ++ ++ + - 
 31 HS 578T ++ - - + 
 32 **MDA-MB-231 + ++ - + 
 33 *MDA-MB-435 - ++ - + 
 34 BT-549 + + - ++ 
 35 *T-47D - - - + 
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 Ovarian 44 *IGR-OV1 + ++ ++ - 
 45 *OVCAR-3 + - - - 
 46 OVCAR-4 - - + + 
 47 *OVCAR-5 - - + ++ 
 48 OVCAR-8 - - ++ - 
 49 SK-OV-3 - - - - 
Prostate 50 DU-145 - - - - 
 51 *PC-3 - - + + 
Renal 52 *786-0 + - ++ + 
 53 A498 - - - ++ 
 54 **ACHN + + - + 
 55 CAKI-1 - - ++ ++ 
 56 RXF 393 - + - + 
 57 *SN 12C + + ++ - 
 58 TK-10 - - + + 
 59 UO-31 - - - - 
 
 
Melanoma 36 LOX IMVI - ++ - +
 37 M14 - ++ - + 
 38 MALME-3M - + - + 
 39 SK-MEL-2 - - - - 
 40 SK-MEL-28 - ++ - - 
 41 UACC-62 - - + + 
 42 UACC-257 + - + - 
- = little to no expression
+ = moderate expression
++ = high expression
* = ARA-211 and Isoproterenol have no effect on pERK levels
** = ARA-211 and Isoproterenol decrease levels of P-Erk1/2
Table. 3  Cell lines from the NCI 60 cell line panel were screened for ARA-
211 sensitivity based on P-Erk1/2 inhibition.  Likewise, the levels of β2 AR, 
P-Erk1/2, C-Raf and B-Raf were analyzed by western blot to determine if 
sensitivity is conferred by C-Raf versus B-Raf expression levels (Figure 
10).
Table 3.  ARA-211 sensitive and insensitive cell lines tested from the 
NCI 60 cell line panel do not correlate with C-Raf and B-Raf expression 
levels
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 β2-AR
P-ERK1/2 
C-Raf
Colon CNS Leukemia
B-Raf
Figure 14.  Western blot verification of β2 AR, P-Erk1/2, C-Raf and B-Raf 
expression levels from the NCI 60 cell line panel
β2-AR
P-ERK1/2 
C-Raf
Lung Mammary Melanoma
B-Raf
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Figure 14 (continued).  Western blot verification of β2 AR, P-Erk1/2, C-
Raf and B-Raf expression levels from the NCI 60 cell line panel
β2-AR
P-ERK1/2 
C-Raf
Melanoma Ovarian Prostate
B-Raf
Renal
β2-AR
P-ERK1/2 
C-Raf
B-Raf
Figure 14.  Western blot analysis of β2 AR, P-Erk1/2, C-Raf and B-Raf 
expression levels from the NCI 60 cell line panel.  Cell lysates were obtained 
from NCI, and western blot anaysis was performed according to Materials 
and Methods.
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 ARA-211 inhibits anchorage independent proliferation, induces apoptosis, 
and suppresses the growth of human tumor xenografts in nude mice only 
in cell lines where it produces cAMP and inhibits P-Erk1/2 levels 
 
 We next determined if ARA-211 suppresses tumor growth only in those 
cells where it inhibits P-Erk1/2 in a cAMP-dependent manner.  To this end, we 
treated with ARA-211 the 6 cell lines identified above and processed them for 
assays for cAMP stimulation (ELISA), anchorage-independent proliferation (soft 
agar growth), apoptosis (TUNEL) and in-vivo tumor growth (xenograft).  Figure 
15 demonstrates the stimulation of cAMP in MDA-MB-231 (breast), SF-539 (cns), 
and ACHN (renal) tumor cell lines by 16, 13, and 16 fold with 10 µM ARA-211 
stimulation.  However, ARA-211 failed to stimulate cAMP in A549 (lung), HCT-
116 (colon) and SNB-19 (cns) (summarized in Table 4).  In agreement with Table 
3, Table 4 also shows that ARA-211 inhibited P-Erk1/2 levels only in cell lines 
where it induces cAMP formation.  Furthermore, Table 4 shows the anchorage-
dependent cell proliferation is inhibited in a dose dependent manner with ARA-
211 treatment of MDA-MB-231, ACHN, and SF-539, but not of A549, HCT-116, 
or SNB-19 cells.  Inhibition of anchorage-dependent growth at 10 µM ARA-211 
stimulation was 60, 55, and 62 percent for ARA-211 sensitive cell lines versus 9, 
6, and 0 percent for insensitive cell lines (Table 4).  There was even greater 
inhibition of anchorage-independent cell proliferation, with sensitive cell lines 
inhibited by 82, 94, and 97 percent, whereas the insensitive cell lines showed 0, 
7, and 5 percent inhibition at 10 µM (Figure 16, Table 4). 
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Figure 15.  ARA-211 induces cAMP formation in MDA-MB-231, SF-539 
and ACHN cells but not in A549, SNB-19 and HCT-116 cells 
Figure 15.  cAMP ELISA assays were used, as described under Materials 
and Methods, to determine the sensitivity of cell lines to ARA-211 mediated 
stimulation of cAMP.
  
Figure 16.  ARA-211 inhibits anchorage independent growth in MDA-
MB-231, SF-539 and ACHN cells but not in A549, SNB-19 and HCT-116 
cells 
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Figure 16.  Anchorage-independent growth on soft agar was used, as 
described under Materials and Methods, to determine the sensitivity of cell 
lines to ARA-211 mediated stimulation of cAMP.
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Figure 17.  ARA-211 induces apoptosis in MDA-MB-231, SF-539 and 
ACHN cells but not in A549, SNB-19 and HCT-116 cells 
ARA-211
Figure 17.  A cell death detection apoptosis ELISA kit was used, as described 
under Materials and Methods, to determine the sensitivity of cell lines to ARA-
211 mediated induction of Apoptosis.
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ARA-211 suppresses tumor growth and causes tumor regression 
 
The ability of ARA-211 to inhibit tumor cell growth and induce apoptosis in 
cultured cells in a β2 AR and Mek1/2-dependent manner suggested that ARA-
211 might induce tumor regression in human cancers where it can induce cAMP 
and block the C-Raf/Mek1/2/Erk1/2 pathway.  Therefore, we determined the 
ability of ARA-211 to interfere with the growth and progression of nude mice 
xenografts of the 6 human cancer cell lines described above.  Figure 18-19 and 
Table 4 shows that ARA-211 was only able to suppress tumor growth in human 
tumors (MDA-MB-231, and ACHN) where β2AR stimulation occurs but not in 
those (A-549, SNB-19, and HCT-116) in which it does not.  Figure 18 
demonstrates that treatment with ARA-211 (i.p.) of mice bearing established 
MDA-MB-231 breast tumors under the mammary fat pads suppressed growth at 
100mpk/day and actually caused tumor regression at 200mpk/day. In the same 
MDA-MB-231 mammary fat pad model, isopreterenol at 200mpk/day did not 
cause tumor regression and inhibited tumor growth by 89% (data not shown).  
After two weeks of treatment with ARA-211 and total tumor regression the mice 
were taken off of the treatment regiment and monitored for tumor growth for an 
additional three weeks, during which none of the tumors regrew and remained 
undetectable (data not shown).  Similarly, the growth of ACHN renal tumors was 
inhibited when the mice were treated i.p. with ARA-211 (75 mpk/day) and tumor 
growth was blocked at 200 mpk/day (Figure 18, 200 mpk day 12 (see ↑).  SF-539 
cells did not grow consistently in nude mice, so no in-vivo data was collected. 
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Figure 18.  ARA-211 treatment of MDA-MB-231 xenografts results in 
tumor regression, and treatment of AHCN xenografts completely 
inhibits tumor growth in nude mice
Figure 18.  ARA-211 suppresses tumor growth and causes tumor regression.  
MDA-MB-231 cells were implanted under mammary fat pads (A.), and ACHN 
were implanted s.c. in nude mice (B.), and the mice treated (i.p.) either with 
vehicle (square )or ARA-211, 100mpk/day (MDA-MB-231, closed triangle), 200 
mpk/day (MDA-MB-231, open triangle), 75mpk/day ( ACHN open circle) or 200 
mpk/day (ACHN starting day 12, see ?) as described under Materials and 
Methods. 
A.
B.
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Figure 19.  ARA-211 treatment of mice bearing A549, HCT-116 and SNB-
19 xenografts has no effect on tumor growth
Figure 19. ARA-211 does not inhibit tumor growth in A549, HCT-116 or SNB-19 
cell lines.   A-549 (A.), HCT-116 (B.) and SNB-19 (C.) were implanted s.c. in 
nude mice and the mice treated (i.p.) either with vehicle (square) or 75mpk/day 
(circle) as described under Materials and Methods. 
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MDA-MB-231 SF-539 ACHN A-549 HCT-116 SNB-19
β2-AR Expression
P-Erk1/2              
(% Inhibition)
100 100 91 0 0 0
cAMP (Fold Induction) 16.7 ± 5.4 13.1 ± 3.0 16.5 ± 3.2 1.3 ± 0.3 1.1 ± 0.1 1.2 ± 0.4
Anchorage Dependent 
Growth (% Inhibition)
60.6 ± 6.5 55 ± 6.9 62 ± 12.7 9.6 ± 6.1 6.5 ± 4.0 0 (n=3)
Anchorage Independent 
Growth (% Inhibition)
82.7 ± 7.9 94.4 ± 1.5 97.9 ± 1.2 0 (n=6) 7.3 ± 3.1 5.1 ± 5.0
Apoptosis              
(% Induction) 15 ± 4.0 9 ± 1.7 11.4 ± 1.9 3.1, 2.2 0, 1.2 0, 0
Tumor Growth in Mice  
(% Inhibition)
100 * 100 0 0 0
Table 4.  ARA-211 inhibits tumor growth and induces apoptosis only in 
human cancer cell lines where it induces cAMP and lowers P-Erk1/2 
levels
Table 4.  Summary of physiological effects of ARA-211 mediated inhibition of P-
Erk1/2 compared to vehicle, β2 AR expression, induction of cAMP and 
apoptosis, inhibition of anchorage dependent and independent cell growth, and 
inhibition of tumor growth in nude mice xenografts.
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ARA-211 in-vivo treatment suppresses P-Erk1/2 levels, inhibits tumor 
growth and induces apoptosis in human xenografts in nude mice 
 
Treatment with 200 MPK ARA-211 in the MDA-MB-231 xenograft model 
resulted in complete tumor regression, which left no tissue available at the end of 
the study for Immunohisctochemical (IHC) evaluation.  Therefore, we repeated 
the xenograft study with 75 MPK to elicit a response to ARA-211 but allow for 
partial inhibition of tumor growth.  Figure 20 shows that treatment of mice with 
ARA-211 (75 mpk/day) inhibited tumor growth by 63%.  Two hours after the final 
treatment the mice were euthanized, and the tumors were harvested and snap 
frozen.  Tumors from MDA-MB-231 tumor xenografts treated with ARA-211 (75 
mpk/day i.p.) or vehicle were analyzed by IHC for inhibition of P-Erk1/2, inhibition 
of proliferation (Ki-67), and induction of apoptosis (TUNEL).  Tumors from ARA-
211 treated mice had a significant decrease in cells staining positive for P-Erk1/2 
(62%, p = 0.02) and Ki-67 (38% P = 0.007) along with a significant increase in 
cells staining positive for TUNEL (6-fold, P =0.0045).   
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Figure 20. In-vivo treatment with ARA-211 suppresses P-Erk1/2 levels, 
inhibits tumor cell growth and induces apoptosis in human xenografts
in nude mice
Figure 20. ARA-211 suppresses P-Erk1/2 levels in human xenografts in nude 
mice.  A. MDA-MB-231 cells were implanted under mammary fat pads and the 
mice treated with vehicle (square) or ARA-211 (circle, 75mpk/day) as described 
previously.  B. Tumors were removed on day 12 and processed for P-Erk1/2 
levels (IHC) as described under Materials and Methods. * p < 0.05.  
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Figure 20 (continued). In-vivo treatment with ARA-211 suppresses P-
Erk1/2 levels, inhibits tumor cell growth and induces apoptosis in 
human xenografts in nude mice
Figure 16. ARA-211 inhibits proliferation and induces apoptosis in human 
xenografts in nude mice.  MDA-MB-231 cells were implanted under mammary 
fat pads and the mice treated with vehicle (square) or ARA-211 (circle, 
75mpk/day) as described previously, tumors removed on day 12 and processed 
for proliferation (Ki-67) (A.) and apoptosis (Tunel) (B.) as described under 
Materials and Methods.  * p < 0.05.
A. B.
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Discussion 
 
A chemical biology approach was used to interrogate aberrant signal 
transduction circuits in human cancer cells about the importance of the β2 
adrenergic receptor in regulating cell division and tumor survival.  Our studies 
clearly demonstrated that activation of the β2 adrenergic receptor by ARA-211 
results in inhibition of anchorage-dependent and –independent tumor cell growth 
as well as induction of apoptosis, and tumor regression in human tumors where 
stimulation of the β2AR results in blockade of the C-Raf/Mek1/2/Erk1/2 pathway.  
The mechanism by which ARA-211 inhibits the C-Raf/Mek1/2/Erk1/2 involves a 
cAMP-dependent PKA but not EPAC activation, as shown in Figure 21.  This 
result was surprising in that PKA is traditionally known as a protooncogene.  The 
fact that PKA can modulate C-Raf activity is known, but the mechanism by which 
PKA regulates C-Raf is controversial(61).  Studies using radiolabeled 
phosphopeptide mapping for C-Raf demonstrated that serine 43 was the major 
residue directly phosphorylated by PKA in-vivo, but did not affect the kinase 
activity of C-Raf(133).  This suggests that PKA either phosphorylates another 
inhibitory residue on C-Raf, or that PKA indirectly decreases the binding affinity 
of C-Raf for Ras.  Other data suggests that inhibitory phosphorylation of serine 
259 by PKA on C-Raf mediates the negative regulatory effects of PKA on the 
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Raf/Mek/Erk1/2 cascade(112).  We investigated the affects of PKA activation by 
ARA-211 treatment of MDA-MB-231 cells on the phosphorylation of C-Raf on 
serine 43 and 259 residues, but did not find any changes compared to control 
treatments.    It is possible that another proposed mechanism by which PKA 
indirectly inhibits C-Raf through activation of Rap-1 leading to competition for 
binding sites on Ras is occurring in MDA-MB-231 cells.  However, we analyzed 
the levels of GTP-loaded Rap-1 from MDA-MB-231 cells treated with or without 
ARA-211, but did not find a difference in activated Rap-1 (data not shown). 
Therefore, our data suggests that the signaling mechanisms by which PKA 
controls C-Raf kinase activity in these breast cancer cells is more complex and 
will require more interrogation.   
Data obtained from our ARA-211 studies clearly demonstrates that ARA-
211-mediated inhibition of tumor cell growth is rescued by β2 AR antagonists, 
suggesting that growth inhibition requires β2 AR signaling.  This is consistent 
with other studies that showed that isoprenaline, cholera toxin, forskolin, and 8-
bromo-cAMP inhibit DNA synthesis and cell growth in normal cells(67, 134).  
However, these studies failed to interrogate the signaling responsible for these 
inhibitory effects.  Increases in cAMP levels have also been shown to inhibit 
mitosis and MMP expression in MDA-MB-231 cells(67).  These data, taken 
together with others demonstrating the ability of cAMP to regulate MAPK-Erk 
signaling and proliferation in normal cells, suggest that cAMP signaling may have 
tumor suppressive effects.  However, this thesis work provides the first 
comprehensive examination of the tumor suppressive effects of cAMP 
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stimulation by a β2 AR agonist in multiple cancer cell lines both in-vitro and in-
vivo. 
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Figure 21.  ARA-211 stimulates crosstalk between β2 AR and 
Raf/MEK/Erk1/2 resulting in inhibition of P-Erk1/2 through a cAMP-
dependent activation of PKA but not EPAC.
Figure 21.  Schematic representation of crosstalk between signaling from ARA-
211-stimulated β2 AR to the Raf/MEK/Erk1/2 pathway through PKA or EPAC 
intermediates.
Src
β2AR
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Another important finding from our studies is that cAMP induction by ARA-
211 treatment induces apoptosis in cancer cells both in-vitro and in-vivo.  
Currently we do not have evidence that directly relates the inhibition of the 
Raf/Mek/Erk kinase cascade with the induction of apoptosis seen with ARA-211 
treatment, however there is data in the literature supporting the proapoptotic 
functions of cAMP.  These data include investigations showing cAMP induction 
resulting in S and G2/M cell cycle arrest, with cells eventually undergoing 
apoptosis in neuroblastoma and leukemia cell lines(66).  Furthermore, another 
group identified a leukemia cell line that is resistant to cAMP-induced apoptosis 
based on overexpression of Bcl-2(135).  This demonstrates that the apoptosis 
induced by cAMP may be independent of Erk1/2 inhibition, but other groups 
showed that inhibition of Erk1/2 could also lead to apoptosis.  In melanoma cells 
it was shown that S6 kinase (S6K), an effector of Erk1/2 downstream, 
phosphorylates the proapoptotic protein Bad, leading to sequestration in the 
cytoplasm(136).  Therefore, when P-Erk1/2 is inhibited, Bad is not sequestered 
and can localize to the mitochondrial membrane where it blocks the prosurvival 
functions of Bcl-2(136, 137).  Similar studies have demonstrated that inhibition of 
Mek/Erk1/2 signaling results in accumulation of Bim, which ultimately associates 
with Bax, resulting in the induction of apoptosis(138, 139).  Aside from inhibition 
of Mek/Erk1/2 activation, there have been reports of C-Raf modulating apoptosis, 
however these mechanisms were independent of the kinase activity of C-Raf.  
This is the case for Raf-related apoptosis through direct binding and influencing 
of MST2(140).  These mechanisms all represent valid ways by which ARA-211 
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could induce apoptosis.  Further work is necessary to elucidate the exact 
mechanisms causing the ARA-211-mediated induction of apoptosis. 
Our studies also demonstrated that constitutively active Mek1/2 rescues 
from ARA-211 inhibition of tumor cell growth, suggesting that ARA-211 must 
inhibit C-Raf/Mek1/2/Erk1/2 to induce its antiproliferative effect.  This is an 
important finding as a large number of human cancers harbor genetic alterations 
that ultimately result in hyperactivation of the C-Raf/Mek1/2/Erk1/2 pathway.  For 
example, it is estimated that 30% of all human cancers contain Ras mutations 
that lead to hyperactivation of this pathway(9). And yet, some tumors with 
activated Ras do not have hyperactivactivated Erk1/2 due to activation of MAP 
kinase phosphatases.  Similarly, a great majority of human cancers over express 
or contain constitutively activated receptor and non-receptor tyrosine kinases 
and/or growth factor autocrine loops that also result in hyperactivation of the C-
Raf/Mek1/2/Erk1/2(141-144).  More importantly, hyperactivation of this pathway 
is critical to the growth and survival of human tumors(72, 77).  Finally, thwarting 
this pathway in human cancers may result in great benefits in the treatment of 
cancer patients since the genetic aberrations (i.e. Ras mutations, EGFR and 
ErbB2 overexpression) that result in hyperactivation of the C-Raf/Mek1/2/Erk1/2 
pathway have all been associated with poor prognosis, resistance to therapy and 
shortened patient life(69, 70, 145, 146).   
Using β2 stimulation to cause tumor regression by blocking the C-
Raf/Mek1/2/Erk1/2 pathway is a novel and powerful approach that could have a 
widespread use in cancer therapy.  Indeed, tumors activate this pathway with a 
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broad spectrum of growth factors/cytokines and their receptors.  For example, 
many growth factors such as EGF, PDGF, FGF, VEGF, IGF-1, heregulin and 
others all activate this pathway(72, 112, 141, 147).  Therefore, tumors that 
express two or more of these growth factors may require a cocktail of anticancer 
drugs.  In contrast, β2AR stimulation will block activation of the C-
Raf/Mek1/2/Erk1/2 pathway when it is driven by several growth factors since they 
all required Mek to activate Erk1/2(48, 53, 61, 62, 76).  For example, we have 
shown that growth factor (i.e. EGF) stimulation of P-Erk1/2 is blocked by ARA-
211 in MDA-MB-231 cells (data not shown). 
This approach, however, is limited to those human tumors that express 
the β2AR and where stimulation of this receptor results in blockade of C-
Raf/Mek1/2/Erk1/2.  In normal cells it has been shown that adrenergic stimulation 
can either stimulate or inhibit P-Erk1/2 and proliferation(34, 35, 48).  However, in 
tumor cells, it is not known if stimulation of the β2AR can stimulate 
tumorigenesis.  In some normal cells expressing B-Raf, β2 adrenergic receptors 
stimulate Erk1/2 by activating B-Raf which in turn activates Mek1/2(33, 148) 
while in other normal cells, β2 adrenergic receptors inactivate Erk1/2 by blocking 
C-Raf(50, 57, 59, 60).  Therefore, β2 adrenergic receptors may also inhibit or 
stimulate Erk1/2 and proliferation in tumors.    
To translate these important results to clinically relevant findings, fresh 
human tumor biopsies were used to determine the effects of β2 AR stimulation 
on P-Erk1/2 levels in β2 AR expressing tumors, as well as to determine if the 
ability of β2 AR stimulation inhibits proliferation and/or induces apoptosis.  
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Chapter 2 focuses on the effects of ARA211 on fresh human tumor biopsies from 
the operating rooms at Moffitt Cancer Center.  The fact that ARA-211 (pirbuterol) 
has previously been used orally and locally (149-151) in humans to evaluate its 
potential as an anti-asthmatic and for the treatment for congestive heart failure 
will facilitate its testing as an anti-cancer drug in hypothesis-driven clinical trials 
with patients where β2AR stimulation is predicted to block C-Raf/Mek1/2/Erk1/2. 
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Chapter 2
 
Determining the Prevalence of β2 AR expression and P-Erk1/2 Activation in 
Fresh Biopsies: ARA-211 Ex-vivo Studies 
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Abstract 
 
In Chapter 1 of this thesis we have demonstrated that stimulation of the β2 
AR with ARA-211 induced tumor suppression by a mechanism involving a cAMP-
dependent activation of PKA, which in turn inhibited C-Raf and its downstream 
effectors Mek1/2 and Erk1/2.  While this is an important finding, its benefit to 
patients will depend on confirming that β2 AR has tumor suppressor activity in 
patient tumors.  Furthermore, based on our data in human cancer cell lines, it is 
anticipated that only certain patients whose tumors express the appropriate 
markers will benefit from this novel therapeutic approach.  Therefore, it is critical 
that fresh patient biopsies first be examined for the levels of β2 AR as well as 
activation of Erk1/2, and that we determine whether the treatment of these fresh 
biopsies with ARA-211 ex-vivo leads to tumor growth suppression.  In this 
chapter we determined by tissue array as well as fresh biopsies from Moffitt 
Cancer Center that approximately 25% of human tumors express both P-Erk1/2 
and β2 AR.  Furthermore, ARA-211 treatment ex-vivo of these fresh patient 
samples followed by immunohistochemical staining of the tissue for P-Erk1/2, β2 
AR, Ki-67 for proliferation, and TUNEL for apoptosis, revealed that the effects are 
highly variable and need to be confirmed by xenograft studies of fresh biopsies.   
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Introduction 
 
Recently the adrenergic receptor/trimeric G-protein/Adenyl Cyclase/cAMP 
pathway was shown to crosstalk to the RTK/Ras/Raf/Mek/Erk pathway in a tissue 
specific manner in normal cells.  Both α and β isoform subtypes have been 
shown to crosstalk with MAP kinase cascade via Gαs, Gαi, and βγ activation(49, 
152, 153).  In some normal cell types such as adipocytes, endothelial cells, 
fibroblasts, smooth muscle cells, hepatocytes, pancreatic acinar cells (AR42J), 
and bone cells (MG63), β2 AR stimulation of cAMP production results in 
inhibition of the Ras/Raf/Mek/Erk pathway (60).  The mechanism by which β2 
AR-mediated formation of cAMP blocks the Raf/Mek/Erk pathway is not well 
understood.  For example, some reports have suggested a cAMP-dependent 
activation of PKA, which phosphorylates C-Raf and inactivates it.  Other reports 
described a cAMP/PKA activation of Rap1, which binds Ras and inhibits its 
binding to C-Raf (60).  Finally, others have shown that cAMP can activate the 
guanine nucleotide exchange factors EPAC1/2 that activate Rap1, which binds 
Ras and inhibits binding and activation of C-Raf (36, 37).  In these cells where 
β2AR stimulation shuts down the Ras/Raf/Mek/Erk pathway, normal cell 
proliferation is inhibited. 
On the contrary, in normal cells such as cardiac myocytes, rat thyroid 
cells, bone cells (ATDC5, MC4), prostate (PC12) and, sertoli cells, granulosa 
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cells, preadiposities, neuronal, and pituitary cells (GH4C1/GH3 cells), β2AR 
stimulation of cAMP formation results in activation of the B-Raf/Mek/Erk pathway 
enhancing cell proliferation, inducing differentiation, or protection from apoptosis 
(32, 34, 126).  Unlike the normal cells where cAMP production results in inhibition 
of C-Raf, in these normal cells cAMP production appears to be stimulating B-Raf.  
Here again, several mechanisms have been proposed by which the increase of 
cAMP results in the activation of B-Raf.  One of these proposes a cAMP 
activation of EPAC, which activates Rap1 to activate B-Raf by an as yet unknown 
mechanism.  Another reported mechanism involves cAMP activation of PKA, 
which activates Src, in turn activating Rap1 to activate B-Raf(34).  Here PKA 
directly phosphorylates Src on serine 17, leading to activation of Rap-1 through 
exchange factors activated indirectly by Src(109).   
In contrast to normal cells, little is known about the role of β2AR 
stimulation in tumor growth and survival.  The previous chapter demonstrated 
that activation of the β2 AR in tumor cell lines MDA-MB-231, ACHN, and SF-539 
resulted in induction of cAMP and subsequent stimulation of PKA kinase activity 
resulting in inhibition of C-Raf, but not B-Raf, kinase activity and inhibition of 
anchorage-dependent and -independent cell proliferation, induction of apoptosis, 
and inhibition of tumor growth in nude mice.  It was also shown that these 
physiological effects were dependent on cAMP activation of PKA, but not EPAC, 
that resulted in the inhibition of Erk1/2 phosphorylation.  However, these results 
relied only on cell lines, and we felt that translating these important findings to the 
clinic is critical.  In order to do this we first needed to confirm our results and 
 87
conclusions in fresh human biopsies.  There were several questions we needed 
to address; these are: 1. What is the prevalence of β2AR expression and P-
Erk1/2 levels in fresh human biopsies?  2. Are there certain tumor types that 
express these important markers, whereas others do not express these markers?  
3. Are tumors that express β2AR and P-Erk1/2 more sensitive to ARA-211 than 
those that do not, as we have seen in cell lines?  4. Are there any human tumors 
where ARA-211 may actually stimulate proliferation? 
In this chapter we describe our work where we examined fresh tumor 
biopsies from patients from Moffitt Cancer Center for expression of β2AR and P-
Erk1/2, as well as the effects of ARA-211 ex-vivo treatment of these fresh 
biopsies on P-Erk1/2 levels, tumor cell proliferation, and apoptosis to answer 
these questions.  In this chapter we determined by tissue array as well as fresh 
biopsies from Moffitt Cancer Center that approximately 25% of human tumors 
express both P-Erk1/2 and β2 AR.  Furthermore, ARA-211 treatment ex-vivo of 
these fresh patient samples followed by immunohistochemical staining of the 
tissue for P-Erk1/2, β2 AR, Ki-67 for proliferation, and TUNEL for apoptosis, 
revealed that the effects are highly variable and need to be confirmed by 
xenograft studies of fresh biopsies. 
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Materials and Methods 
 
Human Tissue Array  
 
Using stage oriented human cancer tissue microarrays (Imgenex, Inc., San 
Diego, CA, catalogue # MB2 60), 56 tumor samples were analyzed for β2 AR 
and MAPK expression by immunohistochemistry (four cores revealed no 
evidence of tumor). The tumors included invasive ductal carcinomas from breast 
(8); medullary carcinoma of breast (2); hepatocellular carcinomas (10); 
transitional cell carcinomas of the bladder (9); mucinous adenocarcinoma of 
urachal remnant (1); papillary serous cystadenocarcinomas of the ovary (9), 
mucinous cystadenocarcinoma of the ovary (1); pancreatic duct 
adenocarcinomas (10); prostatic adenocarcinomas (6). The patients had an 
average age of 59 years (range 16 to 85). Thirty were male and 26 were female. 
The tumors were staged according to the TNM system, following the 
recommendations of the American Joint Committee on Cancer, 5th Edition. The 
stage of the tumors was as follow: 4 patients had stage I, 9 stage II, 28 stage III, 
and 15 stage IV disease. 
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Immunohistochemistry.  
 
Anti-β2 Adrenergic Receptor (β2 –AR) rabbit polyclonal antibody (H-73; sc-9042, 
Santa Cruz Biotechnology, Inc., dilution: 1: 400) and phospho ERK1/2 rabbit 
monoclonal antibody (20G11; Cell Signaling Technology, Inc., dilution 1:200) 
were applied to 3µM sections from formalin fixed, paraffin embedded tissue 
specimens, using the avidin-biotin-peroxidase complex method (Vectastatin Elite 
ABC Kit, Vector, Burlingame, CA), following the manufacturer’s instructions. 
Slides were blocked with normal serum for 20 minutes, followed by incubation 
with the Anti-β2 Adrenergic Receptor and the p-ERK 1/2 primary antibodies, at 
the dilution given, for 60 min.  After rinsing with PBS for 5 minutes, sections were 
incubated with a biotinylated secondary antibody for 20 min.  Following washing 
with PBS for 5 minutes, slides were incubated with avidin-biotin complex for 30 
minutes and washed again. Chromogen was developed with 10 mg of 3,3 
diaminobenzidine tetrahydrochloride (Sigma, St. Louis, Mo) diluted in 12 mL of 
Tris buffer, pH 7.6  for 2 minutes.  All samples were lightly counterstained with 
Mayer's hematoxylin for 30 seconds before dehydration and mounting.  Positive 
controls (cell line and non-stained tissue) and non-immune protein-negative 
controls were used for each section.  No antigen retrieval was performed. The 
stain was semi-quantitatively examined by a board certified molecular 
pathologist.  The positive reactions of each of the antibodies were scored into 
four grades according to the intensity of the staining: 0, 1+, 2+, and 3+. The 
percentages of β2 -AR, and p-ERK1/2 positivity in the tumor cells were also 
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scored into four categories: 0 (0%), 1 (1% to 25%), 2 (26% to 50%), 3 (51% to 75 
%), 4 (76% to 100%) as determined by pathological scoring. The sum of the 
intensity and percentage scores was used as the final staining score. The final 
staining pattern of the tumors is defined as follows: 0 to1, negative; 2 to 3, weak; 
4 to 5, moderate; 6 to 7, strong. 
 
Treatment of Patient Samples Ex-vivo 
 
Fresh human tumor tissue samples were taken from biopsies or resections at 
Moffitt Cancer Center and immediately placed in RPMI media containing 20% 
calf serum.  Samples were cut into thin sections using a surgical scalpel and 
placed in placed in 24 well plates with media completely covering the tissue.  
Samples were treated with vehicle (0.1% DMSO) or ARA-211 at 100 µM for 2 
and 18 hours.  These time points were selected to minimize the potential for 
tissue necrosis to occur.  Tissue was collected at these time points and fixed in 
10 % neutral buffered formalin for at least 48 hours.  Fixed samples were taken 
to the histology core facility at the University of South Florida College of Medicine 
for immunohistochemical staining for P-Erk1/2, β2 AR, Ki-67 and TUNEL.  
Staining analysis and slide quantitation was provided by the Moffitt Cancer 
Center Pathology Core Facility. 
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Results 
 
Tissue arrays and fresh human biopsies reveal human tumor samples that 
express β2 AR and have activated Erk1/2 
 
 To determine if patients could benefit from ARA-211 therapy for cancer we 
first determined if human tumor tissue expressed the β2 AR, which is necessary 
for ARA-211 to induce cAMP through adenyl cyclase activation, as well as 
whether they contained persistently active hyper-phosphorylated Erk1/2.  To this 
end, we first determined the levels of β2 AR in a human tumor tissue array that 
contained tumor specimens from breast, liver, bladder, ovary, prostate and 
pancreatic tissue (Figures 22-27, Table 5).  Strong to moderate cytoplasmic β2 
AR immunostaining (final score between 4 and 7), was observed in 100% of 
prostate  (6/6) (Figure 27) and breast (10/10) (Figure 22) carcinomas, 
independently of the tumor subtype; 80% of ovarian carcinomas (8/10) (Figure 
25); 70% of pancreatic cancers (7/10) (Figure 26); 55% of bladder tumors (5/9) 
(Figure 24), and in only 30% of hepatocellular carcinomas (3/10) (Figure 23). 
One of the two ovarian tumors with low final β2 AR score (3) was a mucinous 
cystadenocarcinoma. Six (60%) of the hepatocellular carcinomas, 4 (44%) 
bladder transitional cell carcinomas, and 1 (10%) of the pancreatic cancers 
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demonstrated no β2 AR expression (final score 0).  Moderate to strong P-Erk1/2 
reactivity (final score between 4 and 7) was observed in 50% of the ovarian 
tumors (5/5) (Figure 25); 2 of 10 bladder tumors (20%) (Figure 24); 2 of 6 
prostate cancers (33%) (Figure 27); 2 of 10 breast cancers (20%) (Figure 22), 
and in only 1 of 10 pancreatic tumors (10%) (Figure 26).  All of the other tumors 
examined were found to be P-ERK1/2 negative (final score 0). The P-Erk1/2 
immunostain localized to both nucleus and cytoplasm of the tumor cells, in the 
majority of the positive cases.  In general, β2 AR was more commonly expressed 
in this array than P-Erk1/2.  β2 AR was expressed in all breast and ovarian 
samples and in 90% and 75% of pancreatic and prostate samples.  A significant 
inverse correlation between β2 AR and P-Erk1/2 staining was observed in 31 of 
56 cases (55%).  All together the data from the tissue array demonstrated that 
even with a small sample size we were able to identify human tumors that 
express both the β2 AR as well as P-Erk1/2.  In fact, approximately 20 percent of 
the tissue analyzed expressed both protein markers.  Furthermore, ovarian 
cancer appears to have the highest frequency of expression of both markers 
(50%), followed by prostate (25%) and breast (20%).  On the other hand, liver, 
bladder and pancreas tissues have the lowest with 0, 10 and 10%, respectively.  
These findings suggest that there may be patient populations whose tumors 
express both β2 AR and high levels of P-Erk1/2 which may respond favorably to 
ARA-211 therapy. 
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Breast infiltrating 
duct carcinoma II
Breast infiltrating 
duct carcinoma III
Breast infiltrating 
duct carcinoma III
Breast infiltrating 
duct carcinoma III
Breast infiltrating 
papillary carcinoma III
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 22. Tissue array identifies human breast tumor samples that 
express β2 AR and P-Erk1/2 
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Breast infiltrating 
duct carcinoma III
Breast mixed 
infiltrating duct and 
lobular carcinoma III
Breast medullary
carcinoma II
Breast atypical 
medullary carcinoma II
Breast infiltrating 
duct carcinoma III
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 22 (continued). Tissue array identifies human breast tumor 
samples that express β2 AR and P-Erk1/2 
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Fi ure 23. Tissue array identifies human liver tumor samples that 
express β2 AR and P-Erk1/2 
g
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Liver hepatocellular 
carcinoma II
Liver hepatocellular 
carcinoma II
Liver hepatocellular 
carcinoma III
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hepatocellular and 
cholangiocarcinoma III
Liver hepatocellular 
carcinoma III
Tissue Array
Sample P-Erk1/2 β2 AR
samples that express β2 AR and P-Erk1/2 
Figure 23 (continued). Tissue array identifies human liver tumor
 
 
 
 
 
Urinary bladder 
mucinous 
adenocarcinoma
Urinary bladder 
transitional cell
carcinoma IV
Urinary bladder 
transitional cell
carcinoma IV
Urinary bladder 
transitional cell
carcinoma IV
Urinary bladder 
papillary transitional 
cell carcinoma IV
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 24. Tissue array identifies human bladder tumor samples that 
express β2 AR and P-Erk1/2 
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Urinary bladder 
papillary transitional 
cell carcinoma IV
Urinary bladder 
transitional cell
carcinoma III
Urinary bladder 
papillary transitional 
cell carcinoma I
Urinary bladder 
transitional cell
carcinoma III
Urinary bladder 
transitional cell
carcinoma III
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 24 (continued). Tissue array identifies human bladder tumor 
samples that express β2 AR and P-Erk1/2 
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Ovary papillary serous 
cystadenocarcinoma 
Ovary papillary serous 
cystadenocarcinoma I
Ovary papillary serous 
cystadenocarcinoma 
Ovary papillary serous 
cystadenocarcinoma 
Ovary papillary serous 
cystadenocarcinoma 
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 25. Tissue array identifies human ovarian tumor samples that 
express β2 AR and P-Erk1/2 
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Ovary papillary serous 
cystadenocarcinoma 
Ovary papillary serous 
cystadenocarcinoma I
Ovary papillary serous 
cystadenocarcinoma III
Ovary mucinous 
cystadenocarcinoma 
Ovary serous 
cystadenocarcinoma 
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 25 (continued). Tissue array identifies human ovarian tumor 
samples that express β2 AR and P-Erk1/2 
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Pancreatic ductal 
adenocarcinoma I
Pancreatic ductal 
adenocarcinoma II
Pancreatic ductal 
adenocarcinoma III
Pancreatic ductal 
adenocarcinoma I
Pancreatic ductal 
adenocarcinoma I
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 26. Tissue array identifies human pancreatic tumor samples that 
express β2 AR and P-Erk1/2 
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Pancreatic ductal 
adenocarcinoma III
Pancreatic ductal 
adenocarcinoma V
Pancreatic ductal 
adenocarcinoma III
Pancreatic ductal 
adenocarcinoma III
Pancreatic ductal 
adenocarcinoma III
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 26 (continued). Tissue array identifies human pancreatic tumor 
samples that express β2 AR and P-Erk1/2 
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Prostate 
adenocarcinoma 
Prostate 
adenocarcinoma 
Prostate 
adenocarcinoma 
Prostate 
adenocarcinoma 
Prostate 
adenocarcinoma 
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 27. Tissue array identifies human prostate tumor samples that 
express β2 AR and P-Erk1/2 
ND
ND
ND = Not Determined
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Prostate 
adenocarcinoma I 
Prostate 
adenocarcinoma 
Prostate 
adenocarcinoma III
Prostate 
adenocarcinoma 
Tissue Array
Sample P-Erk1/2 β2 AR
Figure 27 (continued). Tissue array identifies human prostate tumor 
samples that express β2 AR and P-Erk1/2 
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0
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2575
Prostate
(n =9)
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Pancreas
(n =10)
50100
Ovary
(n =10)
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Bladder
(n =10)
040
Liver
(n =10)
20100
Breast
(n =10)
β2 AR & P-
Erk1/2 cβ2 AR aTissue Type
a - % of tumors positive for β2 AR
b - % of tumors positive for P-Erk1/2
c - % of tumors positive for both
Table 5.  Summary of tissue array staining results for β2 AR and P-
Erk1/2 
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Fresh human tumor biopsies from Moffitt Cancer Center were obtained to extend 
the findings of the tissue array to fresh samples.  The tissues were then fixed in 
10% neutral buffered formalin and stained for expression of β2 AR and P-Erk1/2.  
Results obtained from these tissues were similar to the tissue array in that 
approximately 28 percent of the tissues stained positive for both β2 AR as well as 
P-Erk1/2 (Table 6).  Figure 28 demonstrates the typical staining patterns of both 
β2 AR and P-Erk1/2 in the fresh human tumor biopsies.  P-Erk1/2 staining is 
localized to both the nucleus and cytoplasm, whereas β2 AR staining is seen 
mostly in the cytoplasm and somewhat around the plasma membrane.  Table 6 
further characterizes the staining percentages seen in the tumor biopsies 
collected from all tissue types.  Results from the fresh biopsy samples differed 
from those of the tissue array in that tumors from the liver, colon and pancreas 
demonstrated the highest percentage of co-staining for the β2 AR and P-Erk1/2 
at 50%.  Interestingly, 100% of the liver, retroperitoneal and pancreatic tumor 
tissues showed moderate to strong staining for β2 AR, however even in some 
tissues that expressed high β2 AR levels there were still high levels of P-Erk1/2 
co-expressed.  This suggests that either the activating ligands for the β2 AR are 
not present, or that β2 AR signaling does not result in inhibition of the C-
Raf/Mek/Erk pathway in these tissues.  Ultimately, 56% of all tumor types tested 
showed β2 AR staining.  In contrast to the tissue array staining results in which 
β2 AR staining was more prevalent than P-Erk1/2, the samples collected from 
Moffitt Cancer Center demonstrated similar staining percentages for P-Erk1/2 at 
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57%, compared to β2 AR at 56%.  The differences in staining between the two 
sets of tissues may be due to the wider variety cancer tissues obtained from 
Moffitt Cancer Center, compared to the 6 tumor types from the array.  100% of 
the sarcomas, brain tumors, and mediastinum tumors demonstrated staining for 
P-Erk1/2, although the sample size for these tissues were low.  Likewise, 50% of 
the tumors tested for 12 of the 15 tumor types showed expression of P-Erk1/2.  
These findings confirm that there may be a patient population whose tumors 
express both β2 AR and high levels of P-Erk1/2, however we do not know if 
stimulation of the β2 AR in these tumors will result in decreases in P-Erk1/2, 
inhibition of cell proliferation or induction of apoptosis. 
 
Pt Sample
Liver  
Lung
Lung
Mediastinum
Pancreas
+ + + + +
P-Erk1/2                β2AR
+ +                        +
+                             + +
+ +                        +
+ + +                       + +
Figure 28.  Fresh patient samples from Moffitt Cancer Center express β2 
AR and P-Erk1/2 
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 Table 6.  Summary of fresh human tumor biopsy  staining results for β2 
AR and P-Erk1/2 
3310033
Sarcoma
(n=3)
03333
Stomach
(n=3)
406060
Kidney
(n=5)
3366100
Retro-peritonel 
(n=3)
507550
Colon
(n=4)
206060
Breast
(n=5)
5050100
Liver
(n=6)
60
P-Erk1/2b
4060
Lung
(n=5)
β2 Ar & 
P-Erk1/2c
β2 ARaTumor Type
a - % of tumors positive for β2 AR
b - % of tumors positive for P-Erk1/2
c - % of tumors positive for both
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Omentum
(n=2)
100100100
Mediastinum
(n=1)
β2 Ar & 
P-Erk1/2c
P-Erk1/2bβ2 ARaTumor Type
000
Thyroid
(n=1)
01000
Brain
(n=1)
0050
Lymph Node
(n=2)
05050
Head and Neck
(n=2)
5050100
Pancreas
(n=2)
Table 6 (continued).  Summary of fresh human tumor biopsy  staining 
results for β2 AR and P-Erk1/2 
Table 6.  Summary of fresh human tumor biopsy staining results for β2 AR 
and P-Erk1/2 as described under Materials and Methods. 
a - % of tumors positive for β2 AR
b - % of tumors positive for P-Erk1/2
c - % of tumors positive for both
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Fresh human tumor samples treated ex-vivo demonstrate variable efficacy 
of ArA-211 
 
The results described under Figures 22-28 and Tables 5 and 6 
demonstrated that about 1/4 (~ 25%) of human tumors analyzed express both β2 
AR and have activated Erk1/2.  We next attempted to determine whether the 
expression of these 2 markers predicts sensitivity to ARA-211 in fresh human 
biopsies treated ex-vivo.  We therefore hypothesized that at least some of the 
human tumors that express both β2 AR and P-Erk1/2 will respond to ARA-211 
treatment ex-vivo, as shown by decreased P-Erk1/2 levels (IHC) and proliferation 
(Ki-67 staining), and increased apoptosis  (TUNEL staining).  To test this 
hypothesis we prepared the fresh biopsies in a variety of ways to optimize 
preserving the human cancer cells as well as to avoid necrosis, independent of 
drug treatments.  The first cohort of samples was processed by mincing the 
tissue to increase the exposure to ARA-211.  Treatments were done in a time 
course of 0.5, 2, 6, 18, and 24 hours at 20 µM to determine the best time point to 
harvest the tissue and analyze expression of P-Erk1/2, β2 AR, Ki-67 and TUNEL.  
Prior to ex-vivo treatment a portion of the sample was taken as a pre-treatment 
sample and analyzed for β2 AR and P-Erk1/2 expression.  Analysis of the treated 
tumor samples revealed severe necrosis induced by mincing, which rendered the 
data obtained uninterpretable.   
The second cohort of samples was subsequently collected and prepared 
for ex-vivo treatment by cutting the tissue into thin slices, and increasing the 
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concentration of ARA-211 from 20 µM to 100 µM to increase the tissue exposure 
to the drug.  Vehicle treated samples were exposed for 24 hours, while ARA-211 
treated samples were exposed for 2, 6, and 24 hours.  Specimens were collected 
and analyzed for P-Erk1/2 and β2 AR expression, along with proliferation and 
apoptosis by Ki-67 and TUNEL staining, respectively.  Upon further examination 
of the results it was determined that the 24 hour time point for the vehicle treated 
sample was too distant from the 2 hour time point to analyze P-Erk1/2 and β2 AR 
expression.  In each case, the vehicle treated samples demonstrated a loss of 
expression of both P-Erk1/2 and β2 AR compared to the pre-treatment samples 
collected before ex-vivo treatments.  Due to the loss of expression in the 24 hour 
vehicle sample we were unable to determine the efficacy of ARA-211 to inhibit P-
Erk1/2.   
Finally, 2 hour and 18 hour time points were used for both vehicle and 
ARA-211 treated samples for the third cohort of patient samples collected.  Aside 
from this difference the samples were treated just as they were in cohort two.  In 
this case 20 fresh biopsies were collected and treated ex-vivo.  Pathological 
analysis determined that interpretable data was obtained using this procedure as 
necrosis was minimized and interfered in only 4 of the 20 samples.  However, in 
some samples necrosis was induced in the ARA-211 treated samples, but not 
the vehicle-treated samples.  Necrosis was determined by pathological analysis 
of HE staining morphology, indicating overall intactness of the tissue before and 
after ex-vivo treatment.  From the remaining samples in the absence of ARA-211 
treatment there were 6 tumors that expressed both β2 AR and P-Erk1/2, 6 
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tumors expressed only the β2 AR, 2 tumors expressed only P-Erk1/2, and 1 
tumor expressed neither β2 AR or P-Erk1/2.  The majority of the ex-vivo treated 
samples did not demonstrate changes in P-Erk1/2 or β2 AR upon ARA-211 
treatment.  In 2 samples, Lung I and Kidney IV, P-Erk1/2 decreased 25% and 
3%, respectively.  These changes did not change staining by Ki-67, but resulted 
in a 15% and 5% increase in TUNEL staining, respectively.  However, 
pathological analysis determined that the TUNEL background staining was high 
for several samples and additional apoptosis markers such as caspase 3 are 
needed.  Ex-vivo treatment resulted in increases in P-Erk1/2 in 4 samples 
(Colon, Lung I, Kidney II, Omentum II), but with no other changes except for a 
50% increase in the Ki-67 staining of the Omentum II sample from 15% to 30%. 
However, in the Lung I sample ARA-211 treatment increased TUNEL staining 
from 5% to 45%, but at 18 hours the sample also exhibited 90% necrosis.  The 
β2 AR staining remained fairly constant at the 2 hour treatment time point among 
most of the samples treated ex-vivo.  An increase in β2 AR expression was seen 
in 4 samples and a decrease was noted in only 2 samples, where the expression 
did not change among the remainder of the 14 samples.  Likewise, the Ki-67 
staining for proliferation exhibited little changes in these samples as well.  Only 3 
samples demonstrated a decrease in Ki-67 positive cells, while 1 sample showed 
an increase.  No correlation was noted between decreases in Ki-67 and 
decreases in P-Erk1/2.  In fact, 2 of the samples in which Ki-67 decreased there 
was no P-Erk1/2 expression, and in 1 sample the P-Erk1/2 staining increased by 
15% while the Ki-67 staining decreased by 30%.  Taken together, based on the 
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limited sample size of 20 and the variability of the results, it is not possible to 
determine whether expression of β2 AR and P-Erk1/2 predicts response to ARA-
211.  Indeed, only 6 samples expressed both β2 AR and P-Erk1/2.  Furthermore, 
the necrosis observed not only interfered with the quality of the data, but also 
made it difficult to interpret the data.  This led us to question whether slices of 
tumor biopsies were the best approach to answer the questions we posed.  
Therefore, our conclusion is that an alternative approach must be utilized.  To 
this end, perhaps using fresh tumor biopsies that have been passaged in nude 
mice to select for tumors that grow in-vivo is a better approach(154).
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Proposed method of selecting patients for evaluating the efficacy of ARA-
211 clinically 
 
 Ultimately, the goal of treating patient samples ex-vivo is to determine 
which, if any, patients would benefit from ARA-211 therapy for cancer.  To this 
end we have proposed a flow chart for the identification of patients who may be 
candidates for ARA-211 therapy (Figure 25).  Patient samples that have been 
archived in the tissue bank at Moffitt Cancer Center will be screened for 
expression of P-Erk1/2 and β2 AR expression.  Those that do not express both 
protein markers will be considered off study, while those that express both 
markers will have a tumor biopsy done to confirm the current expression levels.  
These biopsies will also be used for ex-vivo treatment to determine the sensitivity 
of the samples to ARA-211 treatment.  Those samples in which treatment 
decreases the levels of P-Erk1/2, decreases proliferation by Ki-67 staining, or 
increases apoptosis by TUNEL staining will be considered on study for treatment 
with ARA-211.  Those ex-vivo treated samples that exhibit no change or an 
increase in P-Erk1/2, Ki-67 or a decrease in TUNEL will be off study. 
IHC on archived samples
+ β2-AR, + P-Erk1/2 - β2-AR, - P-Erk1/2
+ β2-AR, - P-Erk1/2
- β2-AR, + P-Erk1/2 Off Study
Fresh biopsy 
+ β2-AR, + P-Erk1/2
Off Study
Ex-vivo treatment
- β2-AR, - P-Erk1/2
+ β2-AR, - P-Erk1/2
- β2-AR, + P-Erk1/2
P-Erk1/2
Ki-67
TUNEL
On Study
P-Erk1/2
Ki-67
TUNEL
No ∆ /
No ∆ /
No ∆ /
Off Study
Figure 30.  Patient treatment with ARA-211 requires pre-determination 
of β2 AR and P-Erk1/2 expression, as well as ex-vivo treatment to 
determine efficacy to inhibit proliferation and induce apoptosis
Figure 30.  Flow chart schematic for selection of patients whose tumor may be 
susceptible to ARA-211 therapy.
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Discussion 
 
The use of pirbuterol for cancer therapy is a realistic goal given the 
preclinical data demonstrated in Chapters 1 and 2 of this thesis as well as the 
extensive clinical data in the literature for the broncho- and vaso-dilatation 
properties of pirbuterol as a specific β2 adrenergic receptor agonist.  In fact, 
pirbuterol was approved by the FDA as an anti-asthmatic delivered by nebulizer.  
Because of this, pirbuterol has been tested extensively in animals and humans, 
and the toxicity profiles along with the pharmacokinetics and pharmacodynamics 
are well defined.  In order to effectively treat cancer though, we first need to 
determine which tumors are most likely to respond to pirbuterol by inhibiting 
proliferation and inducing apoptosis.  Previous data from Chapter 1 
demonstrated that the antitumor effect of pirbuterol depends on its ability to bind 
the β2 AR and to inhibit Erk1/2 phosphorylation.  Therefore, we hypothesized 
that patient samples must express the β2 AR along with high levels of P-Erk1/2 
for the treatment to be effective.  Until now there was not much known about 
expression of the β2 AR in human tumors, and the link between β2 AR and P-
Erk1/2 signaling was only demonstrated in certain cells in vitro.  This led us to 
first investigate the expression of these protein markers in tissue arrays from 
human tumors.  To our surprise we discovered that the β2 AR is ubiquitously 
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expressed in all tumor types, with 100% of ovarian and breast tissues staining 
positive.  Furthermore, 90% and 75% of the pancreas and prostate tumors tested 
expressed β2 AR, based on the tissue array results.  It was also surprising that 
the localization of the β2 AR was in the cytoplasm and not in the plasma 
membrane.  One possible explanation for this mislocalization is that the antibody 
concentration used to stain the tissue was too high.  Non-specific staining could 
account for false positive staining in areas such as the nucleus and cytoplasm.  
Better characterization of the antibody, and optimization of staining 
concentrations should be done for future studies using IHC to identify β2 AR 
expression in human tumor biopsies.   
In contrast to β2 AR, P-Erk1/2 levels were found in only 10-50% of 
pancreas, bladder, breast, prostate and ovarian cancer samples, and none of the 
liver cancer samples tested stained positive for P-Erk1/2, based on the tissue 
array results.  With regards to the tissue that expressed both β2 AR and P-
Erk1/2, we found tissue from ovarian cancer having the highest frequency (50%) 
followed by prostate (25%), breast (20%), bladder (10%) and pancreas (10%).  
On average 20% of the tissues from all tumor types stained positive for both β2 
AR and P-Erk1/2.  These data suggest that about 20% of human tumors may be 
susceptible to pirbuterol therapy.  However, as discussed in the introduction to 
Chapter 2, in some normal cells β2 AR stimulation leads to an increase in P-
Erk1/2 levels resulting in stimulation of cell proliferation through B-Raf activation.  
In our human cancer cell line studies in Chapter 1, β2 AR stimulation did not 
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result in stimulation of proliferation in any of the cell lines used; whether this 
occurs in fresh biopsies is not known.  It is therefore critical that the studies of 
Chapter 1 in human cancer cell lines be extended to fresh human biopsies.  It is 
anticipated that β2 AR stimulation will result in inhibition of P-Erk1/2, but clearly 
any patient whose tumor responds to pirbuterol by increasing P-Erk1/2 would not 
be a candidate for β2 AR agonist treatment.  In order to determine how human 
tumors respond to pirbuterol we treated patient fresh biopsies ex vivo, and 
utilized IHC, Ki-67 and TUNEL staining to determine the ability of pirbuterol to 
inhibit P-Erk1/2, and cell proliferation and to induce apoptosis.  From the studies 
we have carried out we conclude that treating fresh biopsies in tissue culture 
poses challenges that were not overcome.  Primarily, the biggest obstacle was 
the inability to preserve the viability of the tumor tissues and stop the necrosis 
that led to lack of consistency among the responses to treatment.  For example, 
the expression of P-Erk1/2 did not change much following ARA-211 treatment in 
most samples, whereas in some the expression increased and in others it 
decreased.  Aside from the technical setbacks, analysis of the limited numbers of 
samples where the staining was clean did not reveal a correlation between 
inhibition of P-Erk1/2 and inhibition of proliferation or induction of apoptosis.  
Furthermore, tumor cell proliferation rates increased in a few samples that did not 
even appear to express the β2 AR.  Another issue that was not totally overcome 
by the third cohort of samples was the necrosis in some biopsies that occurred 
after as little as 18 hours of incubation.  Even more surprising was the data that 
showed that there was more necrosis induced in the treated samples than the 
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vehicle samples ex-vivo.  ARA-211-induced necrosis was not seen in tissue 
culture, as the primary cause of cell death was determined to be apoptosis by 
TUNEL staining (Chapter 1).  TUNEL results for apoptosis may have been 
masked in the ex-vivo studies due to high background staining, most likely due to 
the necrosis seen in the samples.     
Further research needs to be done in the area of ex-vivo treatment of 
patient samples to determine the efficacy of pirbuterol treatment in order to push 
β2 AR therapy into the clinic.  One way to deal with the issue of necrosis is to 
implant small pieces of the patient fresh tumor biopsies into the flanks of athymic 
nude mice, and then treat the mice with ARA-211.  Effects of the drug in vivo can 
be determined by measuring the tumor growth in the presence and absence of 
treatment.  Furthermore, the tissue can be harvested from the mice after 
treatment and stained for P-Erk1/2, β2 AR, Ki-67 and TUNEL.  Although, 
generally human tumor fresh biopsy explants in mice have a very low take rate, 
and it may take as many as 10 passages to get enough tumors for antitumor 
efficacy studies, recent studies however, demonstrated that these explants retain 
the majority of their initial characteristics as judged by gene expression 
profiling(154).  
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Chapter 3 
 
RhoB, but not RhoA Overexpression Delays ErbB2- 
Mediated Mammary Tumor Onset and Reduces Tumor Multiplicity  
in Transgenic Mice 
 
All of the work in this Chapter was performed by Adam Carie except for the 
transgene construct generation, which was performed by Cassandra Martin and 
Kun Jiang 
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Abstract 
 
Ras-homologous (Rho) proteins are GTPases that play essential roles in 
regulating cellular functions such as cell cycle progression, actin cytoskeletal 
rearrangement, cell motility, and have a strong link to oncogenic transformation 
and metastasis.  The RhoA-like family of Rho GTPases are very interesting in 
that two of the family members, RhoA and RhoC, are implicated in cell 
proliferation, invasion and metastasis, whereas the third member RhoB has been 
implicated in tumor suppression and induction of tumor apoptosis.  Furthermore, 
RhoB expression was found to significantly decrease as tumors progress in head 
and neck cancer as well as tumors from lung cancer patients.  Although in 
cultured cells, ectopic expression of RhoB antagonizes malignant transformation 
driven by oncogenes such as receptor tyrosine kinases, Ras and Akt, evidence 
for this in-vivo is lacking.  Therefore, we have developed transgenic mouse 
models in which wild type RhoB or RhoA is over expressed in the mammary fat 
pads under the control of the mouse mammary tumor virus (MMTV) promoter.  
The transgenic mice were then crossed with wild type MMTV-ErbB2 over 
expressing mice to determine the effects of RhoB and RhoA on ErbB2-mediated 
mammary oncogenesis.  In this chapter of the thesis, we show that 
overexpression of RhoB, but not RhoA, is sufficient to delay the tumor onset of 
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ErbB2 mediated tumorigenesis.  Furthermore, we demonstrate that RhoB, but 
not RhoA overexpression results in a decrease in tumor multiplicity compared to 
the ErbB2 or ErbB2/RhoA animals.  This work provides validation of the tumor 
suppressive effects of RhoB in a transgenic mouse model, which is lacking in the 
literature to date.  Furthermore, this provides us with the means to dissect out the 
signaling pathways that are affected by tumor suppressive effects of RhoB.  Also, 
the generation of the RhoA and RhoB transgenic mice will allow for the 
determination of physiological events that RhoA and RhoB may play in the 
normal proliferation, differentiation and/or apoptoitic events that mammary ductal 
epithelial cells undergo during the pregnancy cycle. 
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Introduction 
 
Ras-related low molecular weight GTPases of the Rho subfamily act as 
molecular switches to transduce signals to mediate adhesion, morphology, 
motility, and cell cycle progression(155, 156).  On/off cycling of these switches 
are dependent on guanosine nucleotide exchange factors (GEFs) and GTPase 
activating proteins (GAPs) which control the rate of GTP loading and 
hydrolysis(157).  GEFs can be activated by growth factors and cytokines through 
stimulation of receptors upstream, leading to exchange of GDP-bound for GTP-
bound Rho proteins(156, 158).  Under normal physiological conditions Rho 
GTPases are under tight regulation by both guanosine dissociation inhibitors 
(GDIs) and reliance on post-translational modification.  Rho-GDI inhibits 
spontaneous nucleotide exchange and intrinsic GTPase activity, as well as 
masking of the lipid modification required for localization(159-162).  Sub-cellular 
localization of activated Rho family members is crucial for the downstream 
activation of cellular effectors(163).  Membrane localization is achieved through 
post-translational modification of the C-terminal cysteine with a lipid prenyl 
group(163, 164).  Further regulation of some Rho family members (such as 
RhoB) is achieved through additional modification of C-terminal cysteine motifs 
by palmitoylation.  This also affects sub-cellular localization by preventing 
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association with Rho-GDI resulting in a more robust activation(165).  Many of the 
Rho family members have high sequence homology, so localization plays an 
important role in each member’s physiological function.  RhoB is unique among 
the RhoA-like family members in that it can be modified by both farnesyl (F) and 
geranylgeranyl (GG) lipid groups(163).  Prenylation of endogenous RhoB was 
found to be approximately equal, with half of the protein farnesylated and 
localized to the plasma membrane, while geranylgeranylated RhoB was found in 
endosomal compartments(166).  Further studies demonstrated that when 
farnseylated RhoB was inhbited by FTI treatment, the population of 
geranylgeranylated RhoB increased and localized to late endosomal 
compartments(167).  However, the changes in prenylation induced by FTI 
treatment did not result in differences in the antitumor properties of RhoB.  Both 
RhoB-F and RhoB-GG inhibit anchorage-dependent and -independent growth, 
induce apoptosis, inhibit constitutive activation of Erk and insulin-like growth 
factor-1 stimulation of Akt, and suppress tumor growth in nude mice(168). 
The Rho family of proteins can be divided into six distinct sub-families 
based on amino acid sequence and biological function.  These proteins modulate 
many similar biological effects, including growth and cell cycle promotion, 
regulation of gene expression, and induction of actin cytoskeleton re-
organization(169, 170). Many of these family members, such as RhoA, Rac1 and 
cdc42, have been implicated in malignant transformation, invasion and 
metastasis, and drug resistance(87, 171, 172).  One intriguing family of Rho-
GTPases is the RhoA-related proteins, which is comprised of RhoA, RhoB, and 
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RhoC.  Although the three members of this family share an amino acid sequence 
homology of 85%, share GEFs and effectors, and stimulate actin-myosin 
contractility, there are glaring functional differences that may be dictated by 
distinct sub-cellular localization(155, 163, 173, 174).  Despite the amino acid 
similarity, RhoB contrasts with RhoA and RhoC in regulation and in physiological 
effects.  RhoB is tightly regulated at the transcriptional, translational and post-
translational levels.  The half-life (30-120 minutes) of RhoB mRNA and protein is 
much shorter than that of other Rho proteins (18-24 hours).  RhoB expression is 
induced by growth factors, UV-irradiation and many chemical agents.  RhoB is 
also up-regulated during G1 and S phases of the cell cycle(175).  RhoB, but not 
RhoA or RhoC, has been shown to exist within cells in both farnesylated (F) as 
well as geranylgeranylated (GG) forms, and is also modified by the fatty-acid 
palmitoyl group(163).  Similarly, RhoB has been shown to be crucial for stress-
induced apoptosis and anti-neoplastic activity (22, 176).  As opposed to RhoA, 
RhoB has been suggested to have tumor suppressive activity.  This is based on 
data demonstrating that over-expression leads to inhibition of cancer cell 
proliferation, induction of apoptosis, and inhibition of tumor growth in a nude 
mouse xenograft model(168, 177, 178).  Furthermore, RhoB has been shown to 
negatively regulate NFκB gene transcription, leading to apoptosis in response to 
genotoxic stress(179).  Support for the anitneoplastic role of RhoB has been 
sustained clinically by studies demonstrating suppression of RhoB expression in 
invasive carcinoma from head and neck tumors, and loss of RhoB expression 
during human lung cancer progression(22, 23).   
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As opposed to RhoB, RhoA and RhoC expression correlates with tumor 
progression, invasiveness and metastasis(180-183).  RhoA has been implicated 
in activation of STAT3 and STAT5 leading to cell migration, proliferation, and 
epithelial-to-mesenchymal transition (EMT)(184, 185).  Similarly, siRNA to RhoA 
and RhoC inhibits the proliferation and invasiveness of human gastric carcinoma 
by modulating the PI3K/Akt pathway(186).  Microarray analysis of transformation 
by RhoA(Q63L) in NIH3T3 cells demonstrates up-regulation of AP1, E2F and c-
Myc through Rock and other effectors(14).  Likewise, microarray studies in 
MCF10A cells demonstrate that over-expression of RhoC results in up-regulation 
of genes involved in cell proliferation, invasion/adhesion, and angiogenesis(183).  
Similarly, over-expression of RhoA results in up-regulation of proliferative genes 
such as cyclin D1, cyclin-dependent kinase 8, cyclin A2 and HMGI-C(183, 187).  
It is clear from the studies described in the literature from our lab and others that 
though RhoA and RhoB are highly homologous, they play opposing roles in 
oncogenesis, with RhoA having tumor promoting whereas RhoB having tumor 
suppressive activities.  However, these conclusions are based on correlative 
studies in cell culture, nude mice, and human paraffin-embedded biopsies.  To 
gain direct evidence in support of the tumor suppressive and tumor promoting 
activities of RhoB and RhoA, respectively, we created RhoB and RhoA 
transgenic mice under the transcriptional control of the mammary-specific 
promoter, MMTV.  We then crossed these mice with transgenic mice that 
aberrantly express the receptor tyrosine kinase ErbB2, also under the control of 
the MMTV promoter.  These mice were generated to determine the effects of 
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RhoA and RhoB on ErbB2-mediated breast oncogenesis; specifically tumor 
onset, growth rate and multiplicity.  Furthermore, little is known about the role of 
RhoA or RhoB on normal mammary gland morphogenesis.  Therefore, we will 
also use the RhoA and RhoB transgenic mice we have generated to investigate 
the role of these GTPases on the morphological changes that the mammary fat 
pads undergo during pregnancy.  The major stages of mammary gland 
development occur at puberty, from 3 weeks to 3 months of age, and during 
pregnancy, where epithelial cells proliferate, differentiate, and eventually undergo 
involution by apoptosis.  Initial development occurs during and just after puberty, 
where the ductal structures lengthen and branch out filling the mammary fat 
pads.  The rapid onset of ductal epithelial cell proliferation leads to glands that 
are prepared to sustain differentiation and produce milk for the pregnancy stages 
to come(188).  In the early stage of pregnancy the ductal branches undergo 
another round of substantial cell proliferation and the alveolar buds begin to form 
for milk production(189).  Differentiation begins in the second half of pregnancy, 
characterized by the lobuloalveolar phase of growth leading to the cleavage of 
alveolar buds that will become milk-secreting lobules at lactation(190).  This 
stage nears completion by D18 pregnancy, where the alveolar epithelial cells 
produce milk proteins and lipids.  The final stages of gland morphological 
changes occur at involution; after weaning the glands undergo massive 
apoptosis and remodeling(191).  The majority of epithelial cells will undergo 
apoptosis between day 2 and 3 of involution, leading to collapsing of alveolar 
structures and significant remodeling of the glands beginning around day 6 of 
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involution, and lasting until as long as day 21(192, 193).  By utilizing these known 
morphological changes we can identify the stages at which RhoA or RhoB have 
physiological effects on proliferation, differentiation or apoptosis. 
In summary, based on the body of literature supporting contrasting roles 
for RhoA and RhoB, we set out to validate in this chapter our hypothesis that 
RhoB has tumor suppressive activity using transgenic mouse models comparing 
the effects of RhoA and RhoB expression on breast tissue proliferation, 
differentiation and apoptosis, as well as breast tissue neoplasia.  To this end we 
have created transgenic mice that express RhoA or RhoB under the mouse 
mammary tumor virus (MMTV) promoter to determine the physiological and 
morphological effects of these Rho proteins on normal breast tissue.  
Furthermore, we have created bitransgenic mice that express the ErbB2 proto-
oncogene in the mammary fat pads in combination with RhoA or RhoB to 
determine the effects of each Rho protein on the ErbB2-mediated spontaneous 
tumor onset, growth rate and multiplicity. 
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Materials and Methods 
 
cDNAs and Gene Subcloning 
 
To generate the constructs for human RhoB and RhoA containing plasmids 
under the MMTV promoter, approximately 2 µg MMTV-containing human TGF-
alpha gene (Figure 31) along with pcDNA3-HA-RhoB and pcDNA3-HA-RhoA 
plasmids were all digested using EcoRI restriction endonuclease in its 
appropriate NEB buffer.  The Mouse Mammary Tumor Virus (pMMTV-βglobin) 
vector containing the human TGF-alpha gene was supplied by Dr. Richard Jove’s 
lab at Moffitt Cancer Center.  The gene for human RhoB was a gift from Dr. 
Gilles Favre.  The human RhoA gene was a gift from Dr. Channing Der at the 
Lineberger Comprehensive Cancer Center, University of North Carolina at 
Chapel Hill.  This restriction endonuclease digestion resulted in the removal of 
the TGF-alpha gene sequence and linearization of all 3 plasmids.  Following 
digestion, the MMTV vector was treated with calf intestinal alkaline phosphatase 
(CIP) in order to increase ligation efficiency. The RhoB insert, RhoA insert and 
MMTV vector were then isolated via agarose gel (1.5%) electrophoresis (Figure 
32).  The desired bands were then removed from the gel and purified with Bio101 
Geneclean gel extraction kit following the protocol provided in the kit.  EcoRI, 
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XhoI, BglI, SgrAI, XbaI, PvuI and KpnI restriction endonucleases as well as calf 
intestinal alkaline phosphatase (CIP) and T4 DNA ligase were all purchased from 
New England Biolabs (Beverly, MA).  The NotI, BglII and EcoRV restriction 
endonucleases were purchased from Promega (Madison, WI). The Geneclean 
gel extraction kit was purchased from Bio 101 (Carlsbad, CA).     
Figure 31.  MMTV-TGFα construct linearized by EcoRI digestion for 
insertion of human RhoA and RhoB genes
MMTV Vector ~ 5.8 kb
Linearized MMTV Vector
EcoRIEcoRI Globin Poly A MMTV Promoter
EcoRI Digestion
Figure 31. Mouse Mammary Tumor Virus vector map. The MMTV vector 
map shown here indicates the significant restriction endonuclease sites in 
the subcloning of human RhoA and RhoB into this vector as well as the 
linearized vector following EcoRI digestion.
TGFα
TGFα
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The Rho inserts were then ligated to the linearized MMTV vector.  To this end, a 
small volume (<1 µl) of MMTV vector along with 16 times more RhoA insert, 
RhoB insert or no insert was combined with T4 DNA ligase in ligation specific 
buffer.  These reactions were incubated at 16°C for a period of 16 hours. The 
products were once again purified with the gel extraction kit, as noted earlier, in 
order to remove any salt from the ligation buffer that could potentially interfere 
with the next step.  DH10B bacteria cells were then transformed with 1 µl MMTV-
RhoA, MMTV-RhoB or MMTV control purified ligation product in electroporation 
cuvettes.  The cuvettes were each placed in the electroporation machine that 
force current through the sample in order to induce transformation. This 
apparatus was set at 2.5 kV/resistance, 2.45 kV and 129 for resistance.  The 
bacteria were then transferred into 500 µl SOC media and placed in the 37° 
shaker until sufficient bacterial growth was apparent (approximately 1 hour). 100 
µl from each sample was plated onto LB agarose ampicillin plates, and incubated 
at 37°C overnight.  DH10B competent cells and the pcDNA3 vector were 
purchased from Invitrogen (Carlsbad, CA) along with SOC media and LB broth 
base. Bacto-agar was obtained from Difco Laboratories (West Molesey Surrey, 
UK).  Electroporation cuvettes plus were ordered from Fisher (Pittsburgh, PA).  
Maxi prep and mini prep kits were obtained from Qiagen (Valencia, CA).  The 
following oligonucleotide primer sequences were designed based on the RhoB 
and RhoA cDNA and MMTV promoter sequences.  
The following day the MMTV control plate had 12 clones, while RhoA had 
25 clones and RhoB had 50.  10 clones each were picked from the RhoA and the 
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RhoB plates.  These 20 clones were grown in LB overnight and the DNA was 
prepared using a mini prep kit, following the protocol provided in the kit.  The 
purified DNA was then digested with EcoRI, as noted earlier, in order to identify 
clones containing the RhoB or RhoA insert.  RhoB clones positive for an insert 
were then digested with NotI and BglII restriction enzymes, while the RhoA 
plasmids were digested with EcoRV and BglII to identify the clones that 
contained the RhoB or RhoA insert in the correct orientation.  Correctly 
orientated MMTV-RhoB clones result in 6 kb and 463 base pair bands, while 
clones containing an incorrectly orientated RhoB insert results in 6 kb and 288 
base pair bands when digested in this manner. Correctly orientated MMTV-RhoA 
clones would result in 6 kb and 527 base pair bands, while clones containing an 
incorrectly orientated RhoA insert would result in 6 kb and 215 base pair bands 
when digested in this manner.  Three RhoA clones, clones 1, 2 and 8, and two 
RhoB clones, clones 2 and 3, were found to have correctly orientated inserts 
(Figure 31).   
8.4kb
4.8/4.3kb
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Figure 32.  Isolation of MMTV, RhoB and RhoA DNA and confirmation of 
insertion in the correct orientation of RhoB and RhoA sequences in the 
MMTV vector
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Figure 32.  Isolation of MMTV vector, RhoA and RhoB inserts. MMTV 
vector, HA-RhoB insert, HA-RhoA insert isolation through 1.5% agarose
gel electrophoresis following EcoRI digestion. 28 A. illustrates the 
isolation of the 5.4 kb MMTV vector (Lane 1) from the 2.3 kb insert. This 
figure also shows the isolation of the 622 bp HA-RhoB insert (Lane 2) 
from its original pcDNA3 vector. Figure 28 A. shows the isolation of the 
611 bp HA-RhoA insert (Lane 3) from its original pcDNA3 vector. All 
three isolations were executed using EcoRI restriction enzyme. Figure 
28 B. demonstrates ligation of MMTV vector and RhoA or RhoB insert 
mini prep. Figure 28 B. shows 10 clones from the MMTV-RhoA ligation
plate from which plasmids have been isolated and digested with EcoRI
in order to locate clones that had incorporated the RhoA insert. Clones 
1,2,3,5,6 and 8 in this figure contain the RhoA insert. Figure 28 C. 
shows 10 clones picked from the MMTV-RhoB ligation plate from which 
plasmids have been isolated and digested with EcoRI in order to locate 
clones that had incorporated the RhoB insert. Clones 1,2,3,4,5,6,7,8 
and 10 in this figure contain the RhoB insert. All digests were run on 
1.5% agarose gel.
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One RhoA and one RhoB clone were grown separately in large (500 ml) culture, 
producing the desired DNA plasmid.  Qiagen Maxi Prep kits were used to isolate 
the MMTV-Ha-RhoA and MMTV-Ha-RhoB plasmid DNA by following the protocol 
provided with the kit.  The MMTV-Ha-RhoA and MMTV-Ha-RhoB vectors were 
then sequenced at the Molecular Biology Core Facility at Moffitt Cancer Center 
using the following primers (GIBCO BRL Life Technologies, Carlsbad, CA): 
#1 RhoB 5’: ATG GCG GCC ATC CGC AAG AAG C  
Used to sequence RhoB from beginning of insert downstream. 
#2 RhoA 5’: GCT GCC ATC CGG AAG AAA CT  
Used to sequence RhoA from beginning of insert downstream. 
#3 RhoB 3’: CGC AGG CGG TCG TAG TCC TCC  
Used to sequence RhoB from middle of insert upstream to Beta 
Globin portion of vector. 
#4 RhoA 3’: GCC TCA GGC GAT CAT AAT CTT CCT G 
Used to sequence RhoA from middle of the insert upstream to Beta 
Globin portion of vector. 
#5 MMTV 5’: GGC GTA TCA CGA GGC CCT TTC G 
Used with RhoA and RhoB to sequence MMTV promoter from 
beginning of the promoter downstream. 
#6 MMTV 3’: GGG TCC CCA AAC TCA CCC TGA AG 
Used with RhoA and RhoB to sequence MMTV promoter from end 
of the promoter upstream. 
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These sequencing results verified that the RhoA and the RhoB genes were 
successfully inserted downstream of the MMTV promoter, without mutation.   
 MMTV-RhoB and MMTV-RhoA transgenes were then isolated from the 
remaining portions of the MMTV vectors via restriction enzyme digestion and 
agarose gel electrophoresis for the transgene constructs to be inserted into the 
genome of mouse models through oocyte injections.  This step was originally 
intended to be accomplished using KpnI and SgrAI restriction endonucleases for 
the MMTV-RhoB transgene, while the MMTV-RhoA transgene could be isolated 
using XhoI.  The result of this XhoI digest, however, was to cut the MMTV-RhoA 
plasmid exactly in half, resulting in two 3.3 kb bands that overlapped in agarose 
gels.  This problem was solved by adding PvuI restriction endonuclease, which 
cuts the undesired portion of the vector into 2.6 kb and 700 base pair bands 
(Figure 33).  After reaching this step in the transgene generation process, it was 
found that the SgrAI enzyme that had been chosen to digest and isolate the 
MMTV-Ha-RhoB transgene was not functioning correctly (Figure 33).   
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Figure 33. RhoA, but not RhoB DNA insertion is confirmed in MMTV
vector after restriction enzyme digestion
Figure 33.  MMTV-RhoB and MMTV-RhoA transgene isolation. Restriction 
enzyme digestion to isolate the MMTV-RhoB transgene with KpnI and SgrAI
enzymes was done to confirm insertion into the MMTV vector. Lane 1 shows 
MMTV-RhoB plasmid uncut. Lanes 2 and 3 show MMTV-RhoB plasmid 
digested with only SgrAI and KpnI  respectively. Lane 4 shows the result of 
combining these two enzymes. Lane 5 shows the Lambda DNA digest ladder 
used as a standard. Likewise RhoA insertion was verified by restriction 
enzyme digestion. Lane 6 shows MMTV-RhoA plasmid uncut and lane 7 
shows the MMTV-RhoA plasmid digested with XhoI alone.
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Because there was no restriction enzyme that would cut the vector within 200 
base pairs downstream of the poly-A sequence, it was necessary to again 
subclone the MMTV-Ha-RhoB transgene into a new vector in order to acquire a 
unique restriction enzyme site immediately downstream of the transgene.  This 
was accomplished by digesting the MMTV-RhoB transgene with KpnI and XhoI in 
NEB buffer #2, which yielded two bands of interest, one 2.7 kb band and one 600 
base pair band and a third undesired 3.2 kb band (Figure 34 B.). The new vector, 
pcDNA3 (Figure 34 A.) (approximately 5.4 kb), was digested and also linearized 
with these enzymes in NEB buffer #2 and the resulting sticky ends were 
dephosphorylated by incubation with CIP. These three bands were then isolated 
via agarose gel (1.5%) electrophoresis and purified as described above.  The 
pcDNA3 vector was chosen for this model because it contains a KpnI restriction 
site upstream of the XhoI site with a unique XbaI site immediately downstream of 
the cloning site. The pcDNA3 vector and the 2.7 kb band, both containing KpnI 
and XhoI digested ends were then ligated using T4 ligase and the protocol 
mentioned earlier, along with a control lacking the 2.7 kb band.   
Figure 34.  pcDNA3 vector is linearized by KpnI and XhoI digestion and 
MMTV-RhoB is inserted into the plasmid
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Figure 34.  A. The pcDNA3 vector map and insertion of MMTV-RhoB. This 
map shows the restriction sites that were important in the selection of this 
vector for its use in creating the new MMTV-RhoB construct.  B. Isolation of 
pcDNA3 vector and MMTV-RhoB transgene 2.7 and 600 bp bands by XhoI
plus KpnI digestion. Lane 1 shows MMTV-RhoB plasmid digested with KpnI
alone (6.5 kb). Lane 2 shows MMTV-RhoB plasmid digested with XhoI alone 
(3.3 kb, 2.7 kb and 600 bp bands). Lane 3 shows MMTV-RhoB plasmid 
digested with both KpnI and XhoI (3.3 kb, 2.7 kb and 600 bp bands). Lane 4 
shows the pcDNA3 vector linearized through KpnI plus XhoI digestion.
 149
 150
DH10B competent bacteria cells were transformed using the ligation product and 
plated onto penicillin LB plate, following the protocol mentioned above.  The 
control plate grew no colonies, while the ligation plate contained 12 colonies.  
Clones were then picked, cultured and mini-prepped using a Qiagen kit.  The 
resulting plasmid DNA was digested with XhoI, incubated with CIP and run on 
agarose gel (1.0%) in order to locate clones that had the 2.7 kb band integrated 
(Figure 35).  Clones containing this insert would result in an 8.1 kb band, such as 
the clones in lanes 4,6,10 and 11, while those lacking the insert would have a 5.4 
kb band.  The DNA from the pcDNA3 clones that had integrated the 2.7 kb insert 
of MMTV-HA-RhoB transgene were then isolated and used for ligation of the 600 
base pairs band.  Both the pcDNA3 plus 2.7 kb linearized plasmid and the 600 
base pairs insert include two XhoI sticky ends.   
Figure 35.  MMTV-RhoB insertion into the pcDNA3 vector is verified by 
the presence of the 2.7 kb MMTV-RhoB ligation band
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Figure 35.  Verification of pcDNA3 plus MMTV-RhoB 2.7 kb band ligation. 
This gel demonstrates uncut pcDNA3 (Lane1), XhoI digested pcDNA3 (Lane 
2) and uncut clone #5 in lane 3. Clones 5 through 12 all digested with XhoI
are located respectively in lanes 4-11. This gel was run in 1.5% agarose and 
clones 5, 7, 11 and 12, which shift up with respect to lane 2, are positive for 
the 2.7 kb MMTV-RhoB insert.
 151
 152
DH10B cells were then transformed with this ligation product and plated.  
Following the over night incubation, 10 clones formed on the control plate while 
39 grew on the ligation plate with the 600 base pair insert.  12 of the 39 clones 
that resulted on the ligation plate were picked, cultured and purified by mini-prep.  
The DNA was then digested with EcoRI restriction enzyme in order to locate 
clones that had incorporated this 600 base pairs band in the correct orientation.  
Correctly orientated clones resulted in 8 kb and 600 base pairs bands, while 
incorrectly orientated clones resulted in 7.5kb and 1.2 kb bands (Figure 36).             
The two positive plasmids that were found were then sequenced using the 
MMTV and RhoB primers listed above so that the desired orientation and lack of 
mutations could be verified.  Sequencing results confirmed that the MMTV-Ha-
RhoB transgene had been successfully subcloned into the pcDNA3 vector 
without mutation.  The final step in this procedure was to digest 50 µg pcDNA3-
MMTV-Ha-RhoB plasmid with KpnI and XbaI along with digesting 50 µg MMTV-
Ha-RhoA plasmid with XhoI and PvuI, both in 400 µl reactions to isolate the 
transgenes (Figure 37). 
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Figure 36.  Verification of the integration of the 600 bp MMTV-RhoB 
insert
Figure 36.  Verification of the integration of the 600 bp MMTV-RhoB insert. 
After the pcDNA3 plus 2.7 kb band was ligated with the 600 bp band of the 
MMTV-RhoB transgene, clones were picked and digested with EcoRI in order 
to verify integration and orientation of the insert. EcoRI digested pcDNA3 
(Lane 1) and MMTV-RhoB plasmid (Lane 2) are shown as controls in this 1.5 
% gel. The remaining lanes contain EcoRI digested clones 1-14, respectively.  
Clones resulting in a 600 bp band are oriented correctly , while those 
resulting in 1.2 kb band are not and those resulting in neither 500 bp band nor 
1.2 kb band did not integrate the insert.
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Figure 37. Final isolation of MMTV-RhoA and MMTV-RhoB transgenes
Figure 37.  Final isolation of MMTV-RhoA and MMTV-RhoB transgenes.  This 
1.5% gel displays the final isolation of the two desired transgenes. Both 
MMTV-RhoA and MMTV-RhoB transgenes are 3.3 kb in length.  The 
pcDNA3-MMTV-RhoB plasmid is shown uncut (Lane 1), then digested with
KpnI and XbaI resulting in 5.4 kb and 3.3 kb bands (Lane 2). The MMTV-
RhoA plasmid is shown uncut (Lane3), then digested with XhoI and PvuI
resulting in 3.3 kb, 2.6 kb and 700 bp bands (Lane 4).
 154
 155
A small aliquot of these samples were then run on agarose gel.  The transgene 
restriction endonuclease reactions were then submitted to the Moffitt Cancer 
Center Mouse Models Core Facility.    
The first step in the transgenic mouse model generation is the isolation of 
the MMTV-Ha-RhoB and MMTV-Ha-RhoA transgenes via agarose gel 
electrophoresis.  Once this was accomplished, FvB/N strain female mice were 
bred with FvB/N males. 12 hours following copulation, the female was 
euthanized, ovaries and fallopian tubes were harvested. Fertilized eggs (i.e. 
oocytes) were isolated from the reproductive organs.  For each of the RhoA and 
RhoB transgenes about 180 eggs were harvested and microinjected with the 
DNA constructs.  Only one of the two pre-nuclei of each oocyte was 
microinjected with about .003 µl transgene DNA solution (9 femtograms DNA).  
The injected oocytes were then incubated for 24-48 hours at 39°C, the normal 
body temperature of mice.  Once oocytes had divided into two or more cells, 20-
30 of these microinjected eggs were implanted into the fallopian tube of each of 6 
foster mothers.  Of these 180 injected eggs, only about 20% were expected to 
survive. A projected 20% of these expected 36 survivors (approximately 7-8 
mice) should have the transgene incorporated into the genome, assuming that 
the transgenes are not lethal.   
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Southern Blot and Genotyping 
 
One RhoA founder and 5 RhoB founders were identified based on 
genotyping from tail DNA.  The insertion of the transgene was confirmed by 
Southern blot, which confirmed the integration of the MMTV-HA-RhoB or MMTV-
HA-RhoA in B1, B2, B5, B6, and B9 founders, as well as A5 founder (Figure 38).  
Founder mice were tail snipped and ~1 cm of the tail snip was used for each 
mouse for genomic DNA extraction with the DNA-easy kit (Qiagen) following the 
provided protocol.  Southern blot analysis of founder mice was done by isolating 
approximately 5 ug tail DNA, and samples were digested overnight with EcoRI 
restriction enzyme prior to electrophoresis on 0.8 % agarose in TAE gels.  Gels 
were then transferred to Zetaprobe GT (BioRad) membranes. Southern blots 
were hybridized overnight to 32-PdCTP-labelled Rho A or Rho B cDNAs.    
Additionally, F2 generation mice were genotyped by slot blot hybridization of 
genomic DNA isolated from tail biopsies to 32P-dCTP-labelled probes specific for 
non-murine transgene sequences; SV40 poly A signal for MMTV-ErbB2 mice and 
rabbit beta-globin intron for MMTV-Rho A and -Rho B mice.  Slot blot genotyping 
analysis was performed by the Mouse Models Core facility at Moffitt Cancer 
Center as described previously(194).   
Figure 38.  Southern blot of DNA from transgenic founder mice 
confirms integration of RhoA or RhoB into the host genome
Figure 38.  MMTV-HA-RhoA and MMTV-HA-RhoB contructs were given to the 
mouse models core facility at Moffitt Cancer Center to generate transgenic mice 
over expressing the HA-RhoA or HA-RhoB in the mammary fat pads.  DNA 
from the tails of the founder mice were analyzed by southern blot to confirm 
integration into the host DNA.
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DNA Preparation and PCR 
 
The mice were tail snipped and ~1 cm of the tail snip was used for each mouse 
for genomic DNA extraction with the DNA-easy kit purchased from Qiagen 
following the provided protocol.  The purified DNA samples were dissoloved in 
0.1 x TE and stored in 4 degree until PCR reaction was set up.  The standard 
PCR cycles were utilized to examine the presence of transgenic RhoB or RhoA 
genes in the DNA samples. In brief, for each PCR reaction, 50 ng (`0.5-1 µl) of 
DNA was mixed with 1.5µl dNTPs mixture, 5.0µl of 10x buffer, 2 unit Taq 
enzyme, and 100 ng of 5’ and 3’ primer each, the final volume of the reaction 
was supplemented to 50µl with autoclaved DD water. The PCR reactions were 
started at 94 degree for 3 minutes, then 50 degree for annealing for 1min, then 
72 degree for 2 min for elongation. The PCRs were cycled for 35 cycles and the 
PCR products were run in 1.3% agarose gels and the picture taken.  
  
 
Protein Preparation and Analysis 
 
Tissue from tumor resection dissection was homogenized in a lysis buffer 
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM 
phenylmethylsulfonyl fluoride, 1.5 µg each of aprotinin and leupeptin per ml, 10 
mM NaF, and 10 mM NaPPi. The crude lysates were placed on ice for 25 min 
and vortexed every 5 min and finally spun at 13000 rpm for 15 min. The cleared 
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lysates were stored at -80 degree until Western Blotting analysis. 50 µg of the 
lysates was loaded into SDS-PAGE gel and analyzed for each sample. Antigen-
bound antibody was detected by enhanced chemiluminescence Western blotting 
kit (Amersham Pharmacia Biotech, Piscataway, New Jersey).  Anti-HA antiboby 
(12AC5) was purchased from Roche. Monoclonal antibody to β-actin was 
obtained from Sigma.  
 
Tumor Onset, Growth Rate, and Multiplicity Calculation 
 
F1 generations of ErbB2, ErbB2/RhoA and ErbB2/RhoB mice were backcrossed 
to generate F2 litters.  The F2 generation mice were used to study the tumor 
onset of each strain.  Mice were physically checked for new tumors by palpitation 
of the mammary fat pads 3-4 days per week by vivarium technicians as well as 
laboratory staff.  Once mice formed tumors the onset date was noted and tumor 
measurements were taken every other day to determine the growth rates.  
Tumors were measured by digital Vernier caliper, and volume was calculated 
using the formula V = W2 x L, where width is the largest diameter measurements 
and length is the smaller diameter measurement perpendicular to the width.  
Tumors were allowed to grow until the largest diameter reached the pre-
determined size of 2 centimeters.  At this time the mice were sacrificed and 
tumor tissue was harvested.  Tumor growth rates were determined by subtracting 
the volume at time of sacrifice from the first measurable volume and dividing by 
the number of days between the measurements.  Multiplicity was determined by 
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counting the number of distinct tumors at time of sacrifice.  Graph Pad software 
was used for graphical representation and statistical analysis.  Tumor onset data 
was analyzed using a log-ranked (Mantel-Cox) test comparing ErbB2 and 
ErbB2/RhoA or ErbB2 and ErbB2/RhoB mice.  Student’s t-test was used to 
determine statistical significance comparing growth rates and multiplicity for the 
three groups. 
 161
  
 
 
Results 
 
Generation of DNA constructs for the creation of MMTV-HA-RhoB and 
MMTV-HA-RhoA transgenic mice 
 
DNA sequences for the MMTV promoter, HA epitope tagged human RhoB 
and HA tagged RhoA were sourced from vectors containing MMTV-TGFα and 
pcDNA3 vectors containing HA-RhoB and HA-RhoA as described in detail in the 
Materials and Methods.  Figure 39 demonstrates a schematic representation for 
generation of the constructs, where RhoA and RhoB inserts were removed from 
pcDNA vectors and subcloned into the linearized MMTV vector in which the 
TGFα gene was removed.  The insertion of RhoA into the MMTV vector was 
verified by subsequent removal of the HA-RhoA insert and identification by 
agarose gel electrophoresis, as described in Materials and Methods.  However, 
the insertion of RhoB could not be verified by this method.  Ultimately, the HA-
RhoB insert along with the MMTV promoter was removed from the MMTV vector 
and subcloned back into the pcDNA3 vector.  The insertion of MMTV-RhoB was 
then confirmed by excision and identification by agarose gel electrophoresis.  
The MMTV-HA-RhoA and MMTV-HA-RhoB transgenes were removed from their 
plasmid vectors and submitted to the Mouse Models Core facility at Moffitt 
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Cancer Center for injection into FVB/N mouse 0.5 days post coitum zygotes, and 
implanted into the pseudopregnant CDI foster recipients for development. 
 
R
ho
B
Figure 39. Schematic for generation of MMTV-RhoB and MMTV-RhoA 
constructs for generation of transgenic mice that over express human 
HA-RhoB and HA-RhoA under the MMTV promoter
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Microinjection of MMTV-HA-RhoB and MMTV-HA-RhoA inserts into mouse 
zygotes 
 
Fertilized eggs (oocytes) were harvested from the reproductive organs of 
superovulated female FVB/N mice as described in Materials and Methods.  The 
DNA inserts containing MMTV-HA-RhoB and MMTV-HA-RhoA were 
microinjected into approximately 180 zygots each.  Which were then incubated 
for 24-48 hours and, once cell division occurred, 20-30 eggs each were 
subsequently implanted into the oviducts of 6 pseudopregnant CDI mice per 
transgene (12 mice total).  Females implanted with the RhoB-injected embryos 
gave birth to 20 pups, while the females implanted with the RhoA-injected 
embryos give birth to 8 pups. 
 
PCR and Southern blot genotyping reveals 6 MMTV-HA-RhoB founders and 
2 MMTV-HA-RhoA founders 
 
PCR and Southern blots on DNA from tail snips were used to confirm the 
integration of the transgene into the host mouse genome.  Six MMTV-HA-RhoB 
founders and 2 MMTV-HA-RhoA founders were confirmed, and the founders 
were then backcrossed with wild type mice to generate F1 colonies of RhoB and 
RhoA heterozygous mice.  Littermates from the F1 generation were intercrossed 
to increase the portion of transgenic mice and potentially generate homozygous 
RhoB and RhoA transgenic F2 colonies.  The genotyping of the pups from the F1 
 165
and F2 generations was done by PCR as well as slot blot analysis as detailed in 
Materials and Methods.  Furthermore, RhoB and RhoA transgenic mice from the 
F2 generations were crossed with mice that over express the receptor tyrosine 
kinase ErbB2 under the MMTV promoter to study the affects of RhoB and RhoA 
overexpression in the mammary fat pads on ErbB2-mediated breast 
tumorigenesis. 
 
Overexpression of RhoB, but not RhoA, delays ErbB2-mediated mammary 
tumor onset 
 
ErbB2, the Human Epidermal Growth Factor Receptor-2, is the protein 
product of the ErbB2 gene.  ErbB2 is found over expressed in 25-30% of breast 
and ovarian cancers, and confers poor prognosis clinically(195).  Transgenic 
mouse models of breast cancer have been engineered using overexpression of 
both mutated and wild type ErbB2 genes in mammary epithelial cells driven by 
the mouse mammary tumor virus (MMTV) promoter(196, 197).  The exact 
signaling events leading to transformation downstream of ErbB2 overexpression 
are still under investigation, however, signaling through Ras and PI3K are likely 
mediators(89).  The protooncogenic transgenic model of breast tumor formation 
driven by overexpression of ErbB2 has been well characterized and studied 
since the early 1990’s.  With this model, female mice produce spontaneous 
breast tumors around the age of 250 days, which is far less aggressive than the 
mutated Neu transgenic model which develops multiple tumors around 80 
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days(196, 198, 199).  In this Chapter of the thesis we describe work where we 
generated transgenic mice that over express HA-RhoA and HA-RhoB under the 
control of the mouse mammary tumor virus promoter, and crossed these mice 
with transgenic mice that over express the protooncogenic ErbB2 gene under 
MMTV promoter control.  These bitransgenic mice were used to determine the 
tumor effects of the small GTPases in-vivo on ErbB2 breast oncogenesis.   
 Figure 40 shows the percent tumor free animals for the ErbB2 (EE) mono-
transgenic, ErbB2/RhoB (EB) and ErbB2/RhoA (EA) bitransgenic mice.  
Likewise, Table 7 reports tumor onset, growth rates and multiplicity for EE, EA 
and EB mice with statistical analysis.  In accordance with previously reported 
data from the literature, the EE females averaged 246.5 ± 4.6 days to tumor 
onset.  Overexpression of RhoA along with ErbB2 neither significantly enhanced 
nor suppressed tumor onset, with EA females developing tumors at 
approximately 261 ± 9.1 days.  Log-rank statistical analysis was used to 
determine significance of the entire curve of EE compared to EA mice, which 
gave a non-significant p value of 0.514.  Hazard ratio analysis determined that 
EA mice were only 1.14 times more likely to have a delayed tumor onset event 
compared to EE mice.  However, there was a statistically significant delay in 
tumor onset when RhoB was over expressed in concert with ErbB2.  The 
average tumor onset for EB females was 306 ± 10.4 days compared to 246.5 ±  
4.6 for the EE females.  The Log-ranked statistical output gave a significant 
difference between the two groups with a p value of 0.0003.  Hazard ratio 
analysis showed EB females to be over twice as likely to have a delayed tumor 
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onset over the EE females.  The tumor growth rates for all 3 groups showed no 
statistically significant difference, with EE mice growing at 89 ± 10.7 cubic 
millimeters per day, and EA and EB mice growing at 75.1 ± 9.7 (p = 0.16) and 
74.4 ± 7.7 (p = 0.13) cubic millimeters per day, respectively.  Finally, tumor 
multiplicity was calculated to determine if overexpression of RhoA or RhoB 
affected the number of tumors that developed per mouse.  Mice over expressing 
ErbB2 and ErbB2/RhoA developed 2.1 ± 0.22 and 2.1 ± 0.3 tumors per mouse, 
respectively, while mice over expressing ErbB2/RhoB developed a significantly 
lower 1.5 ± 0.15 tumors per mouse (p = 0.018).  Student’s T-test was used to 
determine significance between growth rates as well as multiplicity.   
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Figure 40.  RhoB, but not RhoA over expression results in a statistically 
significant delay in ErbB2-mediated tumor onset  
Figure 40.  Tumor onset dates for bi-transgenic mice over expressing 
ErbB2/RhoB (EB) or ErbB2/RhoA (EA) were compared to tumor onsets for 
mono-transgenic ErbB2 mice as described in Materials and Methods.  
Mouse Age (Days)
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Table 7.  RhoB, but not RhoA over expression results in a significant 
delay in ErbB2-mediated tumor onset and multiplicity, but not tumor 
growth rate
Table 7.  Tumor onset, growth rate and multiplicity for bi-transgenic mice over 
expressing ErbB2/RhoB (EB) or ErbB2/RhoA (EA) were compared to tumor 
onsets for mono-transgenic ErbB2 (EE) mice. Kaplan-Meyer survival curves 
were generated using graph pad software.  Log-ranked and student T-tests 
were used for statistical analysis.
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Taken together, these data demonstrate a tumor suppressive role for RhoB, in 
that RhoB overexpression resulted in a significant delay in tumor onset and 
decreased the overall tumor multiplicity.  In contrast, RhoA had no significant 
effect on ErbB2 oncogenesis.  However, it is not known to what extent RhoB is 
over expressed in the tumor tissue, or which signaling events RhoB affects to 
implement these tumor suppressive effects.  Tumor tissue was harvested after 
development to validate the expression of RhoB and RhoA.  Figure 41 shows the 
western blot analysis of lysates from EB, EA and EE tumors.  Exogenous RhoA 
and RhoB are tagged with an HA epitope for identification, whereas the EE mice 
do not express the HA epitope tag.  All tumors aside from the one from mouse, 
number EB24, demonstrated HA-RhoB expression to some degree.  Figure 41 
also shows that all tumors from HA-RhoA transgenic mice expressed HA-RhoA, 
and that the HA antibody was specific to exogenous RhoB and RhoA as none of 
the tumors from EE mice demonstrated HA expression. 
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Figure 41.  Tumors from EB and EA transgenic mice express RhoB and 
RhoA as determined by detection of HA by western blot
ErbB2/RhoB Tumor Lysate
Figure 41.  Tumors were resected from ErbB2/RhoB, ErbB2/RhoA and ErbB2 
transgenic mice once the maximum tumor size was reached according to 
IACUC guidelines.  Tissue was snap frozen upon collection, homogenized in 
lysis buffer and the protein was separated by 10 % PAGE, as described in 
Materials and Methods. 
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Discussion 
 
 Rho proteins in the RhoA-like family are highly identical and were once 
thought to be evolutionarily redundant because they share many cellular 
functions(155, 174).  However, recently RhoA and RhoB have been shown to 
also have divergent roles in the context of oncogenesis(16, 21, 22, 168).  The 
role of RhoA in cell cycle progression, malignant transformation and tumor 
invasiveness is well established(171, 174, 186).  These traits demonstrate 
physiological necessities for cellular transformation.  RhoA has also been 
associated with STAT3 and STAT5, which leads to increased tumor cell survival, 
cell proliferation, cell migration and epithelial to mesenchymal transition 
(EMT)(184, 185).  RhoB, on the other hand, has recently been shown to 
suppress oncogenic events that lead to tumorigenesis.  Supporting evidence 
comes from data that shows RhoB expression is decreased by upstream 
oncogenic signaling through EGFR, ErbB2 and Ras, which is mediated through 
the PI3K/Akt pathway(15, 16, 200).  Furthermore, ectopic expression of RhoB 
has been shown to inhibit transformation induced by H-Ras and PI3K, overcome 
resistance to chemotherapeutic induced apoptosis and block cell migration and 
invasion(15, 175, 181).  Likewise, ectopic expression of RhoB significantly 
inhibited metastasis in the B16/F10 mouse melanoma animal model, and 
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transgenic mice lacking RhoB showed a higher propensity for chemically induced 
skin carcinogenesis(16).  On the contrary, RhoA did not have tumor suppressive 
activity in any of these events compared to RhoB.  Correlations in the clinic have 
been made in head and neck as well as lung cancers that demonstrate loss of 
RhoB expression as the tumors became more aggressive, from carcinoma in-situ 
to highly infiltrating carcinoma(22, 23).   
 To further elucidate the anti-cancer properties of RhoB we set out to 
determine the effects of overexpression of both RhoA and RhoB on ErbB2 
mediated breast neoplasia.  By utilizing transgenic mouse models we bridge the 
gap of data between ectopic overexpression in-vitro, and the correlative evidence 
from the studies done in human cancer patients.  This strategy allows for 
examination of overexpression of these Rho family members in a physiologically 
relevant setting for breast cancer by producing tissue-specific expression in the 
mammary fat pads.  By crossing these mice with commercially available ErbB2 
transgenic mice we determined that overexpression of RhoB, but not RhoA, led 
to a significant delay in the tumor onset mediated by ErbB2.  RhoA, on the other 
hand, did not affect the onset of ErbB2 mediated mammary tumors.  These 
results were not surprising, however, because RhoA is downstream of ErbB2, 
constitutively expressed and most likely is already activated by ErbB2 in these 
transgenic mice.  Therefore, it is likely that the increased RhoA expression in this 
system is redundant to ErB2 signaling and cannot add to transforming effects.  
RhoB on the other hand, is not constitutively expressed and its expression is 
downregulated by ErbB2 in cultured cells.  Therefore, forced expression of RhoB 
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could antagonize ErbB2 oncogenesis in this model.  This is consistent with our 
work in cell culture that showed that ectopic expression of RhoB blocked ErbB2 
transformation.  RhoB expression in the mammary fat pads also reduced the 
number of tumors that developed per mouse.  This suggests that RhoB not only 
delayed the tumorigenic events, but also reduced the oncogenic potency of 
ErbB2 signaling creating a higher threshold for transformation leading to fewer 
tumor sites in the mammary fat pads.  However, RhoB did not affect tumor 
growth, suggesting that once the ErbB2 oncogenic signaling overcame the tumor 
suppressive threshold of the over expressed RhoB the tumors grew at the same 
rate.  Similarly, overexpression of RhoA did not add to the ability of ErbB2 to 
induce tumor growth in multiple sites, or increase the growth rates of the tumors 
once established.  Once again, this is most likely due to redundancy in the 
signaling between ErbB2 and RhoA.  The mechanism by which RhoB delays 
tumor onset and multiplicity is not known.  We hypothesize that this is most likely 
due to RhoB antagonizing ErbB2 signaling such as those mediated by Ras, 
PI3K, Akt, Erk, and STAT3.  These studies should be done in the mammary fat 
pads prior to tumor onset as well as early on while the tumors are fairly small.  
This would allow for the comparison of the effects of transgene expression on 
signaling in the fat pads just prior to, or during the transition from normal ductal 
epithelial cells to hyperplasia or neo-plasia.  Furthermore, future work should 
investigate the role of RhoB and RhoA on normal breast morphogenesis.  Future 
analysis may be done on the fat pads of RhoA and RhoB transgenic mice by 
comparing timed matings during the proliferative, differentiation, and involution 
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time points.  Here, P-Akt, P-Erk1/2, and P-STAT3 signaling along with HA, RhoB 
and RhoA expression can be analyzed by both western blot and 
immunohistochemistry. 
 These data both support the recent findings of the divergent roles of RhoA 
and RhoB in cancer, as well as bring up additional questions regarding signaling 
events in which RhoB antagonizes, while RhoA potentiates tumorigenesis.  
Future work with this model and the tumors that arise should focus on signaling 
pathways that are responsible for the anti-neoplastic role of RhoB.  Furthermore, 
the physiological consequences of RhoA and RhoB expression in the mammary 
fat pads should be analyzed during the natural progression of fat pads 
throughout pregnancy.  To this end, timed matings should be done to analyze fat 
pads harvested from RhoA and RhoB mice during the proliferative period of early 
pregnancy.  Likewise, fat pads should be harvested from mice at day 18 of 
pregnancy to determine if RhoA or RhoB expression alters the differentiation of 
the ductal epithelial cells that develop glandular structures for milk production.  
Finally, fat pads should be harvested from mice post pregnancy, after weaning of 
the pups, to determine the effects of RhoA and RhoB expression on involution-
induced apoptosis of the ductal epithelial cells.  Taken together, this data clearly 
demonstrate that RhoB suppresses ErbB2-mediated mammary oncogenesis by 
delaying the tumor onset and by decreasing tumor multiplicity.  These studies 
further validate RhoB tumor suppressive activity and enhanced our 
understanding of RhoB’s involvement in the regulation of tumorigenesis.   
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Conclusions and Future Directions 
 
In an attempt to discover novel inhibitors of the Raf/Mek/Erk1/2 kinase 
cascade we identified pirbuterol, a known β2 selective adrenergic receptor 
agonist(150), as an activator of a tumor suppressive pathway that was poorly 
characterized in cancer.  In Chapter 1 of the thesis we demonstrated that in 
MDA-MB-231 (breast), ACHN (renal) and SF-539 (CNS) cancer cells, stimulation 
of the β2 AR with ARA-211 (pirbuterol) led to the production of cAMP and 
activation of PKA, which resulted in inhibition of C-Raf, but not B-Raf, kinase 
activity.  By blocking C-Raf, and subsequently Mek kinase activity, the activation 
of Erk1/2 proteins were inhibited, correlating with inhibition of anchorage-
dependent and –independent cell growth, induction of apoptosis, and complete 
inhibition of the growth of MDA-MB-231 and ACHN xenografts in nude mice.  
Through the use of pharmacological inhibitors, and genetic manipulation, we 
found that the inhibition of C-Raf/Mek/Erk1/2 signaling was dependent on cAMP-
mediated activation of PKA, but not cAMP activation of the guanine nucleotide 
exchange factors EPAC 1 and 2.  Furthermore, we demonstrated that the 
inhibition of cell proliferation in MDA-MB-231 cells was dependent upon the 
ability of ARA-211 to bind β2 AR and to inhibit Mek1/2 activity.   
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 Prior to our studies there was evidence that cAMP can control the 
proliferation of normal cells through regulation of the Raf/Mek/Erk1/2 pathway.  
However, this regulation has been shown to be cell type specific, and can result 
in either activation or inhibition of Raf/Mek/Erk signaling(201).  For example, in 
adipocytes, endothelial cells, NIH 3T3 cells, rat fibroblasts, smooth muscle cells, 
hepatocytes and pancreatic acinar cells the stimulation of cAMP results in 
inhibition of Erk1/2 activation and decreased cell proliferation(40, 48-56).  
However, in rat thyroid cells, bone cells, polycystic kidney epithelium, Sertoli 
cells, cardiac myocytes, granulosa cells, pre-adiposites, pituitary cells and PC12 
cells the stimulation of cAMP results in the activation of Erk1/2 resulting in 
differentiation or stimulation of proliferation(39-46).  As discussed previously, the 
physiological effects of cAMP stimulation have been well characterized in normal 
cells.  The effects of cAMP stimulation has only been studied in a few cancer 
cells, and most importantly until this thesis work, there has never been a succinct 
report detailing the signaling mechanisms by which cAMP affects cancer cells.  
For instance, two reports demonstrated that in MDA-MB-231 (breast), HL-60 
(leukemia) and SH-CY5Y (neuroblastoma) cancer cells stimulation of cAMP 
results in inhibition of DNA synthesis, but no mechanistic signaling studies were 
done(66, 67).  Inconsistent with this, other reports demonstrate that activation of 
β AR results in stimulation of growth in cell lines derived from pancreatic ductal 
carcinoma, as well as pulmonary adenocarcinoma, through activation of 
arachidonic acid(202-204).  Furthermore, the effects or β2 AR stimulation of 
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cAMP production on anchorage-dependent and –independent growth, apoptosis 
and growth of human tumors in nude mice are not known.     
In this thesis we demonstrated that stimulation of β2 AR inhibits 
anchorage-dependent and –independent growth, induces apoptosis and induces 
regression of human tumors in nude mice.  In normal cells, PKA-mediated 
inhibition of C-Raf kinase activity has been demonstrated, although the 
mechanism by which this occurs is still controversial in the literature for normal 
cells, and lacking for cancer cells.  As mentioned earlier in the discussion of 
Chapter 1, we have demonstrated the dependency of the crosstalk between 
cAMP and Raf/Mek/Erk1/2 signaling on PKA-mediated inhibition of C-Raf kinase 
activity, but were unable to pinpoint the mechanism by which this occurs.  It has 
been suggested in the literature that PKA can directly phosphorylate C-Raf on 
inhibitory serine residues 43 and 259, however, we were unable to detect any 
changes in phosphorylation of these residues by western blot analysis.  Further 
studies are warranted to this end, and should include phosphopeptide mapping 
of C-Raf in the presence or absence of ARA-211 to determine the major amino 
acid residues phosphorylated by PKA.  Likewise, the binding partners of C-Raf in 
the presence or absence of ARA-211 should be analyzed by a proteomic 
approach to determine if PKA is activating an inhibitory protein that binds C-Raf 
and sequesters it in an inactive form.  These results would be important in the 
determination of the mechanism by which PKA inhibits C-Raf activity, and could 
lead to the design of better therapeutic approaches to inhibit C-Raf for cancer 
therapy. 
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The studies herein provide significant insight into the tumor suppressive 
activity of the β2 AR in cancer cells, resulting in inhibition of anchorage-
dependent and –independent growth, induction of apoptosis and complete 
inhibition of tumor xenograft growth.  However, from this work we have not 
demonstrated how the cAMP/PKA-dependent suppression of P-Erk1/2 levels  
results in apoptosis.  There are studies in the literature that show that inhibition of 
P-Erk1/2 can lead to apoptosis in cancer cells through modulation of 
mitochondrial-associated proapoptotic proteins such as Bim and Bad(136, 139).  
However, further studies are warranted to determine if the afore mentioned 
Erk1/2 effectors mediate the apoptosis induced via stimulation of cAMP, or if the 
apoptosis events are independent of Erk1/2 activity.  To this end, constitutively 
activated Mek should be overexpressed followed by ARA-211 treatment to 
determine if apoptosis is rescued when Erk1/2 cannot be inhibited by ARA-211.  
Similarly, PKA could be inhibited by H89 or siRNA prior to ARA-211 treatment to 
determine if apoptosis induction is mediated by cAMP/PKA dependent signaling.  
Also, effectors downstream of Erk1/2 such as Bim and Bad should be knocked 
down, and ARA-211-mediated apoptosis should be examined to determine if the 
ablation results in a rescue from apoptosis.   
In Chapter 2 of the thesis we demonstrate from analysis of both tumor 
tissue array and fresh human tumor biopsies that β2 AR and P-Erk1/2 are 
expressed in approximately 25% of the tumors tested.  This data, combined with 
the preclinical data in Chapter 1, led us to believe that ARA-211 treatment was a 
realistic goal for cancer therapy.  Furthermore, the fact that pirbuterol was 
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previously tested clinically in patients with asthma and congestive heart failure 
will allow for an easier transition to anti-cancer clinical testing since the safe 
doses in humans is already known.  However, since in normal cells cAMP has 
been shown to either stimulate of inhibit proliferation, we investigated the 
response of fresh tumor biopsies to ARA-211 treatment ex-vivo.  This method of 
testing ARA-211 in fresh biopsies, unfortunately, yielded highly variable results, 
which in some cases was masked by necrosis.  The detection of β2 AR and P-
Erk1/2 proteins proved to be problematic as well, as the cellular localization and 
staining percentages were not as expected.  Much of the β2 AR staining was 
found in the cytoplasm or nucleus, but was expected to be in the plasma 
membrane.  Similarly, P-Erk1/2 staining was localized to the nucleus and 
cytoplasm, which was expected, but the % positive staining was lower than 
expected.  After consultation with a molecular pathologist it was determined that 
the antibody concentrations for β2 AR and P-Erk1/2 were not correctly optimized.  
The β2 AR antibody concentration was most likely too high exhibiting non-
specific staining, and the P-Erk1/2 antibody was most likely too dilute resulting in 
false negatives for tissues expected to express high levels of P-Erk1/2, such as 
late stage breast and pancreatic tumors.  Aside from optimizing the IHC staining 
procedures, western blot analysis of protein levels could be used to determine 
expression of β2 AR and P-Erk1/2.  However, this method would not account for 
the tumor stroma that was captured with the tumor during the biopsy.  This could 
result in β2 AR and P-Erk1/2 expression detection from blood vessels or 
fibroblasts that are not actually indicative of the expression levels in the tumor.  
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Ultimately, the best method for the detection of the β2 AR would be laser capture 
microdissection (LCM) of tumor tissue, followed by RT-PCR.  Furthermore, 
microarray analysis of LCM from fresh human tumor biopsy treated ex-vivo, with 
and without ARA-211, could be done to distinguish the effects of the treatment on 
global gene expression.  Another approach to determining the efficacy of ARA-
211 on human tumors would be to implant small pieces of the fresh tumor tissues 
in athymic, nude mice, and treat the mice with ARA-211, as discussed earlier.  
This method would not be practical for all patient biopsies, but would serve as a 
good method to determine proof of concept for a human clinical trial.  Ultimately, 
these studies would provide validation of the tumor suppressive effects of β2 AR 
signaling in human cancer.   
Chapter 3 of the thesis focuses on validating the tumor suppressive 
effects of the small GTPase RhoB.  We set out to show that, in-vivo, RhoB can 
suppress the tumorigenic effects of upstream signaling through the ErbB2 
receptor.  As discussed earlier, the ErbB family of receptors is found 
overexpressed or mutated in many human cancers, such as lung, breast, head 
and neck, and bladder(205).  In-vitro data from the Sebti lab and others 
demonstrated the ability of RhoB to abrogate transformation induced by H-Ras 
and PI3K.  Studies also demonstrate that RhoB expression is decreased by 
oncogenic signaling through EGFR, ErbB2 and H-Ras.  Likewise, IHC studies in 
paraffin-embedded tumor specimens from patients with lung and head and neck 
cancer shows that RhoB expression is lost as cancers progress from hyperplastic 
to deeply invasive carcinoma.  However, data supporting the tumor suppressive 
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effects of RhoB in-vivo is lacking.  Therefore, we used a physiologically relevant 
transgenic animal model to test the tumor suppressive effects of RhoB compared 
to its close family member RhoA.  Mice were generated that express RhoB or 
RhoA in the mammary fat pads under the control of the MMTV promoter.  These 
mice were then crossed with mice that overexpress the ErbB2 receptor under the 
same promoter control to create Erb2/RhoB and ErbB2/RhoA bitransgenic mice.  
ErbB2 overexpressing mice are known to develop spontaneous breast tumors at 
approximately 250 days(199).  By introducing human RhoB in the mammary fat 
pads, the tumor onset mediated by ErbB2 was delayed by approximately 60 
days.  This data was statistically significant with a p value of 0.0003 as measured 
by a log-ranked statistical test.  We hypothesized that this delay was due to the 
ability of RhoB to antagonize ErbB2 signaling through Ras, PI3K, Akt, Erk, and 
other well-known downstream ErbB2 signals.  However, gathering data to 
support this hypothesis was difficult as the tumors were allowed to grow to 
maximum capacity to determine the effects of RhoB on tumor growth rate.  It is 
possible that once the tumors were harvested they had already overcome the 
suppressed signaling from RhoB.  To test this hypothesis, fat pads would need to 
be tested in a time course study to determine if RhoB expression resulted in 
inhibition of P-Akt, P-Erk1/2 or P-STAT3 during the transition from normal to 
transformed tissue.  Although the tumor onset was delayed breast tumors 
eventually developed, and the tumor growth rate was not significantly different.  
This suggests that RhoB acts as a gatekeeper for transformation early on.  
However, as the tumors accumulate more oncogenic alterations the RhoB tumor 
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suppressive effects can be overcome.  This may occur through further genetic 
alterations that surpass the regulation of RhoB, or signaling events that could 
eventually lead to expression of negative regulators of RhoB that result in faster 
degradation, or protein turnover.  Time course studies are needed for RhoB 
expression in normal, hyperplasic and transformed cells isolated from the fat 
pads of ErbB2/RhoB bitransgenic mice.  These studies could determine if RhoB 
is suppressed at the transcriptional level by methylation or acetylation during the 
transformation of the mammary ductal epithelial cells, although silencing at the 
promoter level is not likely since RhoB is under the control of the MMTV promoter 
in this case.  However, a proteomic approach could allow for the identification of 
novel proteins that bind and inactivate RhoB.  Here, RhoB would be 
immunoprecipitated from fat pad lysate at different time points and isolated by 
native gel electrophoresis.  Once separated, RhoB binding partners could be 
identified, cloned and tested in tissue culture for their ability to reverse the tumor 
suppressive effects of RhoB.  Although RhoB overexpression did not change the 
growth rate of the tumors once formed, the multiplicity, or tumor number per 
mouse, was significantly decreased by 25% (p value = 0.018) by RhoB, but not 
RhoA.  Once again, the means by which RhoB inhibited tumor multiplicity in this 
setting was not determined, but it suggests that overall the oncogenic potency of 
ErbB2 signaling was diminished to the point that transformation was blocked in 
some of the mammary fat pad tissue.  To gain insight to the mechanism by which 
RhoB decreases the oncogenic potential of ErbB2, microarray studies could be 
done comparing ErbB2 to ErbB2/RhoB and ErbB2/RhoA fat pads. In contrast to 
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RhoB, RhoA, which has been shown to promote tumorigenesis by inducing 
proliferation and contributing to invasion and metastasis, was found to have no 
effects on the tumor onset, growth rate or multiplicity of ErbB2-mediated 
oncogenesis in our transgenic mouse model.  It is likely that the increase in RhoA 
expression is redundant to ErbB2 overexpression and could not add to the 
transforming effects of ErbB2.  For example, ErbB2 is known to activate Ras, 
which in turn, can activate RhoA.  Therefore, overexpression of RhoA in this 
setting would not be expected to add to the transforming activity of ErbB2. 
While the generation of RhoA and RhoB transgenic mice allowed for the 
investigation of the effects of these small G-proteins in ErbB2 breast 
oncogenesis, they will also be instrumental in determining their role in normal 
mammary morphogenesis.  As described previously, future work will be done 
with RhoA and RhoB monotransgenic mice for timed mating experiments to 
analyze their effects on ductal lobular formation, normal cell proliferation at day 7 
pregnancy, differentiation at day 18 pregnancy and apoptosis at day 4 weaning.  
This would allow for the precise timed measuring of the effect of RhoA and RhoB 
on signaling events linked to the induction of apoptosis or inhibition of 
proliferation. 
In conclusion, this work adds significant value to our understanding of the 
tumor suppressive roles of the β2 AR and small GTPase RhoB.  We now know 
that in cancer cells, PKA can mediate crosstalk between the β2 AR and C-
Raf/Mek/Erk1/2 kinase cascade resulting in inhibition of anchorage-dependent 
and –independent tumor cell growth, induction of apoptosis and complete 
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inhibition of human tumor growth in nude mice.  Here we have shown that the 
inhibition of proliferation is dependent on stimulating cAMP production and 
inhibiting Mek/Erk1/2 signaling.  However, translating this work to the clinic 
proved to be problematic.  We determined that approximately 25% of tumors 
tested for β2 AR and P-Erk1/2 actually co-express these markers from IHC 
examining a tissue array and fresh human tumor biopsies from Moffitt Cancer 
Center, but the expression patterns alone do not predict response to ARA-211 
therapy on tissue ex-vivo.  Further testing of ex-vivo tumor treatment techniques 
is necessary in order to more accurately predict a patient’s tumor response to 
ARA-211.  Finally, we provide data that supports the tumor suppressive effects of 
the small GTPase RhoB, but not RhoA, in a transgenic mouse model highly 
relevant to human breast cancer where ErbB2 drives oncogenesis.    Future work 
should include studies designed to interrogate the signaling mechanisms by 
which RhoB delays tumor onset and reduces tumor multiplicity. 
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